activités scientifiques & académiques 2012-2013

of 140 /140
ACTIVITÉS SCIENTIFIQUES & ACADÉMIQUES I 2012-2013 CENTRE HOSPITALIER DE LUXEMBOURG

Author: centre-hospitalier-de-luxembourg

Post on 28-Mar-2016

243 views

Category:

Documents


9 download

Embed Size (px)

DESCRIPTION

 

TRANSCRIPT

  • ACTIVITS SCIENTIFIQUES & ACADMIQUES I 2012-2013CENTRE HOSPITALIER DE LUXEMBOURG

  • SOMMAIRE

    PRFACE 04

    TITRES DE MATRES DE STAGES ET TITRES ACADMIQUES, SITUATION 2013 06

    ACTIVITS SCIENTIFIQUES ET ACADMIQUES PAR SERVICES: 10

    Anesthsie I Ranimation I Policlinique I Urgences adultes I Douleur 10 Cancrologie I Hmatologie 16

    Cardiologie I Maladies vasculaires 26

    Pneumologie I Maladies Infectieuses I Immuno-Allergologie 32 Urologie I Nphrologie I Endocrinologie 49

    Chirurgie gnrale, digestive, vasculaire, thoracique et endocrinienne I 54Hpato-Gastro-Entrologie (UMADE)

    Chirurgie plastique, reconstructive et esthtique I Oto-Rhino-Laryngologie I 64Ophtalmologie I Dermatologie

    Neurosciences 68

    Mdecine interne (Site Eich) 88

    Appareil locomoteur 91

    Clinique Pdiatrique 110

    Gyncologie-Obsttrique 128 Imagerie mdicale 132 Biologie clinique 135

    DIRECTION 136

  • P

    rfa

    ce

    4

    PRFACE

    Bravo tous !Nous pouvons tre fiers de notre hpital !

    Le recueil de lactivit scientifique et de recherche pour les annes 2012 et 2013 montre limportance que cette activit a pris au CHL.

    Nous comptons ainsi pour les deux annes acadmiques 315 publications scientifiques, plus de 300 communications scientifiques et 180 tudes cliniques, translationnelles ou fondamentales auxquelles nos mdecins participent.

    Les deux graphiques ci-joints montrent une volution croissante de cette activit depuis de nombreuses annes. Le facteur dimpact (ISI /Thompson Scientific) des publications se stabilise au-del de 4.

    Nous observons un vritable tissu de connexion nationale et internationale avec des centres hospitaliers et des instituts de recherche qui est la base de cette activit. Cer-taines des publications se sont faites dans les revues les plus prestigieuses comme par exemple en 2013 le New England Journal of Medicine (Targeted temperature management at 33C versus 36C after cardiac arrest, N Engl J Med. 2013 Dec, Stammet P, Werer C).

    Nous tenons vous remercier pour votre engagement exemplaire pour une des missions phare de notre hpital. Nous sommes conscients que cette activit est chaque fois le fruit dune volont et dun engagement personnel dont la valorisation peut paratre insuffisante.

    Notre volont est de mettre disposition de tous les mdecins du CHL une structure de plus en plus performante qui facilitera les dmarches administratives et logistiques en relation avec les tudes scientifiques.

    Ainsi en 2014, nous esprons pouvoir engager un coordinateur de lenseignement mdical et de la recherche qui ensemble avec le bureau acadmique et le secrtariat acadmique sera votre disposition pour vous aider dans vos dmarches.

    Par ailleurs nous allons organiser en 2014 la premire dition de lEducation and Research Day loccasion duquel trois prix vont tre attribus nos meilleurs scientifiques.

    Dr CATHERINE BOISANTE

    Dr GUY BERCHEM Dr MARC SCHLESSER

  • P

    rfa

    ce

    5

  • TITRES DE MATRES DE STAGES & TITRES ACADMIQUES SITUATION 2013 / 1

    T

    itres

    de

    ma

    tres

    de

    stag

    es e

    t titr

    es a

    cad

    miq

    ues

    I Situ

    atio

    n 20

    13

    6

    DPARTEMENT

    Anesthsie/RanimationPoliclinique/Urgences Adultes

    Cancrologie/Hmatologie

    Cardiologie/Maladies Vasculaires

    Pneumologie/Maladies Infectieuses/Immuno-Allergologie

    Urologie/ Nphrologie/ Endocrino-Diabetologie

    NOM

    Dr M. Max

    Dr B. Schmitz

    Dr M. Stein-MergenDr G. BauerDr A. EvenDr G. BerchemDr F. Ries

    Dr J. BeisselDr D. Wagner

    Dr R. Nati

    Dr M. Schlesser

    Dr T. Schmit-StaubDr J.C. Schmit

    Dr R. HemmerDr J.-F. WilmartDr D. PouthierDr C. Atlan

    Dr F. Dadoun

    Dr G. Michel

    FONCTION/TITRE

    Matre de stage

    Weiterbildungsermchtigung fr das Fach AnsthesiologiePrivatdozent

    Lehrbeauftragter fr das Fach AnsthesiologieWeiterbildungsermchtigung fr das Fach AnsthesiologieMatre de stageMatre de stageMatre de stageMatre de stageMatre de stageMatre de stage Matre de stageMatre de stageMatre de stage

    PhDWeiterbildungsermchtigung fr das Fach PneumologieMatre de stageWeiterbildungsermchtigung fr das Fach PneumologieMatre de stagePhD (Doctor in de Medische Wetenschappen)Matre de stage honoraireMatre de stageMatre de stageMatre de Confrences des Universits

    Matre de Confrences des UniversitsMatre de stage Matre de stage Prof. Agrg

    ETABLISSEMENT

    Ministre de la Sant Belge (Formation Anesthsie-Ranimation)rztekammer des Saarlandes

    Medizinische Fakultt der Universitt Erlangen/NrnbergMedizinische Fakultt der Universitt des Saarlandesrztekammer des Saarlandes

    Universit Poincar NancyUniversitt WienUniversit de LuxembourgUniversit de LuxembourgUniversit de LuxembourgMinistre de la Sant Belge (Formation Mdecine Interne)Universit de LuxembourgUniversit de LuxembourgMinistre de la Sant Belge (Formation Cardiologie)Universit Catholique de Louvain Landesrztekammer Rheinland-Pfalz

    Universit de LuxembourgLandesrztekammer Rheinland-Pfalz

    Universit de LuxembourgKatholieke Universiteit Leuven

    Universit libre de BruxellesUniversit Catholique de LouvainUniversit de LuxembourgUniversit de la Mditerrane, Aix-Marseille, FranceUniversit de la Mditerrane, Aix-Marseille, FranceUniversit de LuxembourgUniversit de LuxembourgParis

  • 7

    TITRES DE MATRES DE STAGES & TITRES ACADMIQUES SITUATION 2013 / 2

    T

    itres

    de

    ma

    tres

    de

    stag

    es e

    t titr

    es a

    cad

    miq

    ues

    I Situ

    atio

    n 20

    13

    DPARTEMENT

    Chirurgie Gnrale-Digestive-Vasculaire-Thoracique et Endocrinienne/Hpato-Gastro-Entrologie/(UMADE)

    Chirurgie Plastique, Reconstructive et Esthtique/Oto-Rhino-Laryngologie//Ophtalmologie/Dermatologie

    NOM

    Dr JS. Azagra

    Dr M. Goergen

    Dr J. Weber

    Dr N. Calteux

    Dr E. Panosetti

    FONCTION/TITRE

    Matre de stage

    Charg de Cours (Master in Advanced Laparosc. Surgery)Professeur Honoraire et Charg de Cours (Master in Mini-Invasive Surgery)Lehrbeauftragte fr das Fach ChirurgieMatre de stageWeiterbildungsermchtigung fr das Fach GastroenterologieMatre de stageMatre de stage

    Matre de Confrence CliniqueMatre de stage du 2me cycle Md.Membre enseignant et formateur

    Matre de stageMatre de stage

    Matre de stage ORL et chirurgie cervico-faciale Matre de stage pour tudiantsProfesseur invit

    ETABLISSEMENT

    Ministre de la Sant Belge (Formation Chirurgie Gnrale)Facult de Mdecine de lUniversit de Granada EspagneThe Mini-Invasive Surgical Institut of Caceres J Uson , Universit de Caceres EspagneUniversitt des Saarlandes

    Universit de Luxembourgrztekammer des Saarlandes

    Universit de Luxembourg Ministre de la Sant Belgique (Formation chirurgie plastique)Universit Catholique de LouvainUniversit Catholique de LouvainUniversit Catholique de LouvainCollge Franais de Chirurgie Plastique (enseignement chirurgie plastique)Collegium Chirurgicum Plasticum BelgicumUniversit de LuxembourgMinistre de la Sant Belge(formation ORL)Fdration des Mdecins Suisses(FMH)SuisseUniversit de LigeUniversit de Lige

  • DPARTEMENT

    Neurosciences

    NOM

    Dr L. Le Saint

    Dr C. Pull

    Dr A. Mhe

    Dr S. Beyenburg

    Dr N. Diederich

    Dr D. Droste

    Dr H. Metz

    Dr F. Hertel

    FONCTION/TITRE

    Enseignant en sexologie clinique au dpartement de sciences humaines et psychologie.Membre de la Fdration mdicale Hlvtique (FMH)Prof. associ/Matre de stageProfesseur agrg de Psychiatrie titre trangerProfesseur conventionnProfesseur invitLehrbeauftragterMatre de stageMatre de stageWeiterbildungsermchtigung fr das Fach PsychiatrieLehrbeauftragte fr das Fach PsychiatrieMatre de stageMatre de stage

    Privatdozent

    Volle Weiterbildungsermchtigung fr das Fach NeurologieSenior Clinical researcherVolle Weiterbildungsermchtigungfr das Fach NeurologieAuerplanmiger Professor fr NeurologieVisiting Assistant ProfessorDiplom-Gesundheitskonom BI (Master of Business Administration for Public Health)Auerplanmiger Professor fr NeurologieLehrbeauftragter fr das Fach Neurologie Volle Weiterbildungsermchtigung fr das Fach NeurologieDEGUM-SeminarleiterEEG-AusbilderUltraschall-Ausbilder und -PrferVolle Weiterbildungsermchtigungfr das Fach NeurologieVolle Weiterbildungsermchtigungfr das Fach Neurochirurgie

    ETABLISSEMENT

    Universit de Lorraine Metz-Nancy

    Berne

    Universit de LuxembourgUniversit de Paris V

    Facult de Mdecine de StrasbourgUniversit de LigeUniversit de VienneUniversit de LuxembourgUniversit Catholique de Louvain rztekammer des Saarlandes

    Universitt des Saarlandes

    Universit de LuxembourgMinistre de la Sant Belgique (Formation neurologie)Medizinische Fakultt der UniversittBonnrztekammer des Saarlandes

    Universit de Luxembourg rztekammer des Saarlandes

    Universit de CologneRush University Med. Center, Chicago

    Betriebswirtschaftliches Institut, Kln (depuis 2001)

    Westflische Wilhelms-UniversittMnster (depuis 2005)Universitt des Saarlandes rztekammer des Saarlandes

    Deutsche Gesellschaft fr klinische Neurophysiologie Deutsche Gesellschaft fr Ultraschall in der Medizin rztekammer des Saarlandes

    rztekammer des Saarlandes

    TITRES DE MATRES DE STAGES & TITRES ACADMIQUES SITUATION 2013 / 3

    T

    itres

    de

    ma

    tres

    de

    stag

    es e

    t titr

    es a

    cad

    miq

    ues

    I Situ

    atio

    n 20

    13

    8

  • DPARTEMENT

    Appareil Locomoteur

    Clinique Pdiatrique

    Gyncologie-Obsttrique

    Imagerie Mdicale

    NOM

    Dr. T. Gerich

    Dr D. PapeDr R. Seil

    Dr A. Urhausen

    Dr A. BiverDr. C. de Beaufort

    Dr I. Kieffer Dr R. SeligmanDr JF. Vervier

    Dr J. Bottu

    Dr L. Bindl

    Dr F. De Bruyne

    Dr Jean-Paul Hermand

    Dr D. Van Wymersch

    Dr. W. PilloyDr G. Dooms

    FONCTION/TITRE

    Auerplanmiger Professor fr UnfallchirurgieHabilitation im Fach Orthopdie Matre de stageMdecine gnrale et chirurgie orthopdiqueWeiterbildungsberechtigung Zusatzbezeichnung Sportmedizin Auerplanmiger Professor fr OrthopdieMatre de stageMdecine gnraleWeiterbildungsberechtigung Zusatzbezeichnung Sportmedizin Auerplanmiger Professor fr SportmedizinMatre de stagePhD (Doctor in de Medische Wetenschappen) 1986

    Matre de stageMatre de stageMatre de stage

    Matre de stageMatre de stage

    Matre de stageMatre de stagePrivatdozent

    WeiterbildungsermchtigungFr Kinder- und JugendmedizinLehrbeauftragter fr das Fach FrauenheilkundeDiplme Interuniversitaire dEchographie obsttricale et gyncologique Matre de stage

    ProfesseurMatre de stageMatre de stage

    Privatdozent

    ETABLISSEMENT

    Medizinische Hochschule Hannover

    Universitt des SaarlandesUniversit de Luxembourg

    rztekammer des Saarlandes

    Universitt des Saarlandes

    Universit du Luxembourg

    rztekammer des Saarlandes

    Universitt des Saarlandes Universit de LuxembourgErasmus Universiteit Rotterdam, the Netherlandspdiatre endocrinologue , diabtologue, NVK Universit de LuxembourgUniversit de LuxembourgMinistre de la Sant Belge (Psychiatrie infanto-juvnile)Universit de LuxembourgMinistre de la Sant Belge (Formation Pdiatrie)Universit Catholique de LouvainUniversit de LigeRheinische Friedrich-Wilhelms- Universitt, Bonnrztekammer des Saarlandes

    Universitt des Saarlandes

    Universit Libre de Bruxelles

    Ministre de la Sant Belge (Formation Gyncologie-Obsttrique)Medical University of Southern AfricaUniversit de LuxembourgMinistre de la Sant Belge(Formation Imagerie Mdicale) Universit de Genve

    TITRES DE MATRES DE STAGES & TITRES ACADMIQUES SITUATION 2013 / 4

    9

    T

    itres

    de

    ma

    tres

    de

    stag

    es e

    t titr

    es a

    cad

    miq

    ues

    I Situ

    atio

    n 20

    13

  • A

    ctiv

    its

    scie

    ntifi

    ques

    et a

    cad

    miq

    ues

    au C

    HL

    par

    serv

    ices

    10

    ANESTHSIE

    Appartenance une Socit Scientifique

    B Schmitz : Deutsche Gesellschaft fr Ansthesiologie und Intensivmedizin (DGAI)Wissenschaftlicher Arbeitskreis Kinderansthesie der DGAIEuropean Society for Pediatric Anesthesia (ESPA)Society for Pediatric Anesthesia, USA (SPA)Wissenschaftlicher Arbeitskreis Regionalansthesie der DGAIWissenschaftlicher Arbeitskreis Notfallmedizin der DGAIWissenschaftlicher Arbeitskreis Neuroansthesie der DGAI

    Communication un Congrs / Runion Scientifique

    B Schmitz : Allergisch-bedingte obere Atemwegsobstruktion, KATZ Congress, Kinderspital Zrich (CH), 30.03.-01.04.12

    B Schmitz : Pdiatrische Ansthesie, Fortbildungsvortrag am Klinikum Bad Hersfeld (D), 24.09.2012

    B Schmitz : Evidence based? Fentanyl bzw. Sufentanil ist Remifentanil als Opioid in der Kinderansthe-sie berlegen11. Stuttgarter Kindesansthesietage. 7.-10.11.12

    B Schmitz : S-Ketamin ein spezielles Ansthetikum, Vorlesung in der Friedrich-Alexander-Universitt Erlangen-Nrnberg (D), 10.12.12

    B Schmitz : Neurologische Notflle und Stoffwechselkomata, Vorlesung in der Friedrich-Alexander-Uni-versitt Erlangen-Nrnberg (D), 11.12.12

    B Schmitz : Lokoregionale Ansthesie bei Kindern, ALIAR Luxembourg, Janvier 2013 B Schmitz : Einer meiner grossen Fehler in der Kinderansthesie, Deutscher Ansthesie Congress 2013, Nrnberg, (D) 20.-22.04.2013

    B Schmitz : Ohne Ultraschall geht nichts mehr Auch in der Kinderansthesie ?, Deutscher Ansthesie Congress 2013, Nrnberg, (D) 20.-22.04.2013

    B Schmitz : S-Ketamin ein spezielles Ansthetikum, Vorlesung in der Friedrich-Alexander-Universitt Erlangen-Nrnberg (D), 17.06.13

    B Schmitz : Neurologische Notflle und Stoffwechselkomata, Vorlesung in der Friedrich-Alexander-Uni-versitt Erlangen-Nrnberg (D), 18.06.13

    ANESTHSIE I RANIMATION I POLICLINIQUEI URGENCES ADULTES I DOULEUR 2012-2013 / 1

  • A

    ctiv

    its

    scie

    ntifi

    ques

    et a

    cad

    miq

    ues

    au C

    HL

    par

    serv

    ices

    11

    ANESTHSIE I RANIMATION I POLICLINIQUEI URGENCES ADULTES I DOULEUR 2012-2013 / 2

    Publications scientifiques

    Calteux N, Schmid N, Hellers J, Kumpan S, Schmitz B : Neonatal cleft lip repair: Perioperative safety and surgical outcomes. Ann Chir Plast Esthet. 2013 Dec;58(6):638-43. Facteur dimpact 2012 : 0.322

    RANIMATION, SOINS INTENSIFS MDICO-CHIRURGICAUX/SAMU

    Appartenance une Socit Scientifique

    C Ferretti :European Society of intensive Care Medicine (ESICM)

    C Lorang :European Society of intensive Care Medicine (ESICM)European Society of Anaesthesiology (ESA)

    M Max :European Society of Intensive Care Medicine (ESICM)Society of Critical Care Medicine (SCCM)European Society of Clinical Microbiology and Infectious Diseases (ESCMID)European Society of Anaesthesiology (ESA)Deutsche Gesellschaft fr Ansthesiologie und Intensivmedizin (DGAI)Deutsche Interdisziplinre Vereinigung fr Intensiv- und Notfallmedizin (DIVI)

    L Mertens :European Society of intensive Care Medicine (ESICM)

    L Mnster :European Society of intensive Care Medicine (ESICM)European Society of Anaesthesiology (ESA)Cercle des Anesthsistes-Ranimateurs au Luxembourg, (CMARL),

    P Stammet :European Hypothermia Stroke Research Workshop (EHSRW), (2012)European Society of Anaesthesiology (ESA)European Society of intensive care Medicine (ESICM) Steering Group de lHypothermia Network et de lInternational cardiac arrest registry (INTCAR)Luxembourg TransplantLuxembourg Resuscitation Council (LRC)

  • A

    ctiv

    its

    scie

    ntifi

    ques

    et a

    cad

    miq

    ues

    au C

    HL

    par

    serv

    ices

    12

    ANESTHSIE I RANIMATION I POLICLINIQUEI URGENCES ADULTES I DOULEUR 2012-2013 / 3

    Communication un Congrs / Runion Scientifique

    M Max : Formateur lUniversit de Marburg (D). 17.4.12

    M Max : Prsentation orale au HIFIT. Heidelberger Intensivsymposium. Heidelberg (D). 20.01.12

    M Max : Moderation. 22. Symposium Intensivmedizin u. Intensivpflege. Bremen (D). 22. -24.02.12

    M Max : Frhzeitige Tracheotomie Con. 22. Symposium Intensivmedizin u. Intensivpflege. Bremen (D). 22. -24.02.12

    M Max : Die drei wichtigsten Studien ber Komplikationen inder Intensivmedizin. 22. Symposium Inten-sivmedizin u. Intensivpflege. Bremen (D). 22. -24.02.12

    M Max : New therapeutic fluids for RRT in AKI, International Symposium on Intesive Care and Emergency Medicine, Bruxelles (B). 21 23.03.12

    M Max : Praxis der Citratantikoagulation, Die Hamburger Intensivtage. Universittsklinikum Hamburg-Eppendorf. (D). 20. -21.04.12

    M Max : Formateur lUniversit de Marburg (D). , 24.04.13,

    M Max : Nicht-Invasive Ventilation, Beatmung von A-Z, 6. Klner Intensiv-Forum AINS, Cologne (D), 06.-07.09.13.

    M Max : Schwerpunkt Beatmung : - Beatmung - Was mssen Sie wissen ? - NIV Nutzen und Grenzen.Meet the Expert: - Spezielle Pathophysiologie der Beatmung, Intensivmedizin Kompakt, Heidelberger Interdisciplinres Forum Intensivthrapie (HIVIT) 2013, Heidelberg (D) 16.-19.01.13.

    P Stammet : Biomarkers in the TTM-trial or 11.2 liters of blood. TTM-trial investigator meeting Lund, Sweden 31.05-01.06.2012.

    P Stammet : Le don dorganes, une question de mort et de vie ! le point de vue du ranimateur, confrence dans le cadre du 8e symposium de lALIAR, le 17 novembre 2012 Mondorf les Bains

    Devaux Y, Goretti E, Vaussort M, Zhang L, Wagner DR, P Stammet : Circulating mRNAs after cardiac arrest. Poster prsent au congrs de lEuropean Society of cardiology aot 2012, Istanbul

    P Stammet, Collas D, Werer C, Muenster L, Clarens C., Wagner D. Impact of initial interventions on neu-rological recovery after cardiac arrest : data from the Luxembourg NorthPole cohort. Poster prsent lors de la 4e journe de recherche clinique du CRP-Sant, 24 octobre 2012

    Nielsen N and INTCAR study group *(P Stammet). A Genetic Algorithm Prognostic Tool Nested Within a 2500 Patient Registry of Post Cardiac Arrest Care. Poster prsent lAHA Congress 2012, Los Angeles. (* Dr P. Stammet est membre de ce groupe)

  • A

    ctiv

    its

    scie

    ntifi

    ques

    et a

    cad

    miq

    ues

    au C

    HL

    par

    serv

    ices

    13

    ANESTHSIE I RANIMATION I POLICLINIQUEI URGENCES ADULTES I DOULEUR 2012-2013 / 4

    Seder DB, Unger B, Sunde K, Rubertsson S, Dr P Stammet, Friberg H, Nielsen N. Neurological outcomes of cardiac arrest survivors with myoclonus following resuscitation. Poster prsent lAHA Congress 2012, Los Angeles

    Dr P Stammet, Dr. D Wagner, Dr S. Beyenburg : Le projet NorthPole dans le temps, from bench to bed-side?, Socit Luxembourgeoise de Cardiologie, A.G., CHL Amphi. 09.04.13. Dr P Stammet, Dr. D Wagner, Dr S. Beyenburg

    Publications scientifiques

    Max M Preventing ventilator-associated lung injury at the bedside, Crit Care Med. 2013 Feb; 41(2):683-4. Facteur dimpact 2012: 6.124

    Reintam Blaser A, Poeze M, Malbrain ML, Bjrck M, Oudemans-van Straaten HM, Starkopf J; Gastro-Intestinal Failure Trial Group. Collaborators: De laet I, Bosman RJ, Grigoras I, Blaj M, Stockman W, Lormans P, Ordoez CA, Kirov M, Duchesne J, Brienza N, Sanchez Hurtado LA, Papavramidis T, Tamme K, Aguirre-Avalos G, Onichimows-ki D, Nissar S, Litvin A, Balihar K, Reinikainen M, Zykova I, Edalatnejad M, Chiumello D, Wilson C, Izura J, Soler C, Koroljov A, Kaska M, Max M, Hussien M, Szturz P, Holzinger U, Paasma R, Palibrk I, Kovac N, Plantefeve G, Cheatham M, Ivatury R, Ramos Palomino I, Parm P, Ranjan P, Gonzlez Daz G, De Waele J, Debergh D : Gastrointestinal symptoms during the first week of intensive care are associated with poor outcome: a prospective multicentre study, Intensive Care Med. 2013 May;39(5):899-909. Facteur dimpact 2012: 5.258

    Max M Diagnosing brain death: just a matter of good sense ? Minerva Anestesiol. 2014 Jan;80(1):8-10. Facteur dimpact 2012: 2.818

    Nielsen N, Winkel P, Cronberg T, Erlinge D, Friberg H, Gasche Y, Hassager C, Horn J, Hovdenes J, Kjaer-gaard J, Kuiper M, Pellis T, Stammet P, Wanscher M, Wise MP, neman A, Wetterslev J. : Detailed sta-tistical analysis plan for the target temperature management after out-of-hospital cardiac arrest trial, Trials. 2013, Sep 17;14:300. Facteur dimpact 2012: 2.206

    Nielsen N, Wetterslev J, Cronberg T, Erlinge D, Gasche Y, Hassager C, Horn J, Hovdenes J, Kjaergaard J, Kuiper M, Pellis T, Stammet P, Wanscher M, Wise MP, neman A, Al-Subaie N, Boesgaard S, Bro-Jeppe-sen J, Brunetti I, Bugge JF, Hingston CD, Juffermans NP, Koopmans M, Kber L, Langrgen J, Lilja G, Mller JE, Rundgren M, Rylander C, Smid O, Werer C, Winkel P, Friberg H; TTM Trial Investigators: Tar-geted temperature management at 33C versus 36C after cardiac arrest, N Engl J Med. 2013 Dec 5;369(23):2197-206. Facteur dimpact 2012: 51.658

  • A

    ctiv

    its

    scie

    ntifi

    ques

    et a

    cad

    miq

    ues

    au C

    HL

    par

    serv

    ices

    14

    Nielsen N, Wetterslev J, Al-Subaie N, Andersson B, Bro-Jeppesen J, Bishop G, Brunetti I, Cranshaw J, Cronberg T, Edqvist K, Erlinge D, Gasche Y, Glover G, Hassager C, Horn J, Hovdenes J, Johnsson J, Kjaergaard J, Kuiper M, Langrgen J, Macken L, Martinell L, Martner P, Pellis T, Pelosi P, Petersen P, Persson S, Rundgren M, Saxena M, Svensson R, Stammet P, Thorn A, Undn J, Walden A, Wallskog J, Wanscher M, Wise MP, Wyon N, Aneman A, Friberg H. Target temperature management after out-of-hospital cardiac arrest-a randomized, parallel-group, assessor-blinded clinical trial-rationale and design.Am Heart J. 2012 Apr;163(4):541-8. (Facteur dimpact 2012: 4.497)

    Stammet P, Goretti E, Vausort M, Zhang L, Wagner DR, Devaux Y. Circulating micro RNAs after cardiac arrest Crit care med. 2012 Dec; 40(12):3209-14. doi: 10.1097/CCM.0b013e31825fdd5e. (Facteur dimpact 2012: 6.124)

    Stammet P, Wagner DR, Gilson G, Devaux Y. Modeling serum level of s100 and bispectral index to pre-dict outcome after cardiac arrest. J Am Coll Cardiol. 2013, Aug 27;62(9):851-8. Facteur dimpact 2012: 14.086

    Stammet P, Collas D, Werer C, Mnster L, Clarens C, Wagner D. Impact of initial interventions on long term neurological recovery after cardiac arrest: data from the Luxembourg North Pole cohort. Bull Soc Sci Med Grand Duche Luxemb. 2012;(1):60-70

    Stammet P, Kirchmeyer M, Zhang L, Wagner DR, Devaux Y. The Chemokine (C-X3-C Motif) Receptor 1 is a Candidate Prognostic Biomarker after Cardiac Arrest. J Clinic Experiment Cardiol 2012, S2:004. doi:10.4172/2155-9880.S2-004

    Stammet P, Collas D, Werer C, Mnster L, Clarens C, Wagner D. Impact des premiers gestes sur lvo-lution neurologique long terme aprs arrt cardiaque: donnes du registre luxembourgeois North Pole. Bulletin de lALIAR, Anne 7. novembre 2012, ISSN:1990-0231

    Etudes en cours

    Etude International Cardiac Arrest Registry (INTCAR) , registre europen et nord-amricain des pa-tients bnficiant dune hypothermie thrapeutique aprs arrt cardiaque ranim. P Stammet, membre du steering committee

    Etude North Pole (Biosignatures to predict outcome after hypothermia for patients surviving cardiac arrest), tude monocentrique visant rechercher des biomarqueurs de bon pronostic neurologique chez les patients traits par hypothermie thrapeutique aprs arrt cardiaque. Collaboration : CHL, INCCI, CRP-Sant. Investigateurs principaux : Dr P Stammet (ranimation), Dr. D Wagner (cardiologie, INCCI, CRP-S), Dr S. Beyenburg (neurologie)

    Etude multicentrique randomise Target Temperature Management after out-of-hospital cardiac ar-rest (TTM-trial) National investigator: Dr P Stammet

    ANESTHSIE I RANIMATION I POLICLINIQUEI URGENCES ADULTES I DOULEUR 2012-2013 / 5

  • A

    ctiv

    its

    scie

    ntifi

    ques

    et a

    cad

    miq

    ues

    au C

    HL

    par

    serv

    ices

    15

    ANESTHSIE I RANIMATION I POLICLINIQUEI URGENCES ADULTES I DOULEUR 2012-2013 / 6

    POLICLINIQUE, URGENCES ADULTES

    Communication un Congrs / Runion Scientifique

    B. Metzger, M.A. Dicato, G. Mahon, S Obertin, J. Kayser; Luxembourg/LU, Mutation of either RAS or BRAF correlates with MGMT methylation and mutation of PIK with PTEN methylation, but non of these is associated with stage in colorectal cancer, ESMO, Vienne, (A) 28.09-02.10.12

    R Stein , Prsident : Vieillissement et Reproduction, International Symposium Well Aging, Andropause / Menopause, Sofitel Kirchberg, SLAM, 14-15.06.13

    M. Aubart-Schuller, R Stein, J.C. Leners : Qualicopc : Trial Performance in primary care in Luxembourg : different perspectives (poster).5e Journe de recherche clinique, Luxembourg, 23.10.2013

    F. Raphal, R Stein : La flexibilit en mdecine.Semaine Mdicale de Lorraine Nancy, 18.11.2013

    CENTRE DE TRAITEMENT DE LA DOULEUR

    Communication un Congrs / Runion Scientifique

    C Boisante : Using clinical data in biomedical research: the management of electronic records and data mining for applications relevant to the patient. Panel discussion. 4me Journe de la Recherche Cli-nique, CRP-Sant, Novotel Kirchberg, 24.10.12,

    C Boisante : La dimension thique de la prise de dcision, La chirurgie du quatrime ge, CHL Amphi, Alformec, 08.06.13

    M Schmidt : Algodystrophie aus der Sicht der Schmerztherapie Stand 2013, Vues sur : Algodystrophie Complex Regional Pain Syndrome, Forum Mdical Pluridisciplinaire, SLKS, Coque, 25.09.13

  • A

    ctiv

    its

    scie

    ntifi

    ques

    et a

    cad

    miq

    ues

    au C

    HL

    par

    serv

    ices

    16

    CANCROLOGIE I HMATOLOGIE 2012-2013 / 1

    HMATOLOGIE, HMATO-ONCOLOGIE, CANCROLOGIE

    Appartenance une Socit Scientifique

    G Berchem :Socit Luxembourgeoise dOncologie (SLO) - PrsidentLaboratoire Hmato-Cancro. Exprimental (CRP-Sant) - Directeur American Ass. Cancer Research (AACR)American Society of Clinical Oncology (ASCO)Socit des Sciences Mdicales, Luxembourg.

    M Dicato :American Society of Clinical Oncology (ASCO)European Society of Medical Oncology (ESMO)Fondation de Recherche Cancer et SangSocit Luxembourgeoise dOncologie (SLO)Membre Socit des Sciences Mdicales, Luxembourg.

    S De Wilde :Socit Luxembourgeoise dOncologie (SLO)Belgian Hematological Society (BHS)

    C Duhem :Groupe Sein, CHL - ResponsableComit Scientifique Europa Donna LuxembourgComit Scientifique Europa Donna BelgiqueSocit Luxembourgeoise dOncologie (SLO)Socit Belge de Snologie, Bureau de la Socit

    L Plawny :Belgian Hematological Society (BHS)European Hematology Association (EHA)Socit Luxembourgeoise dOncologie (SLO)

    F Ries :Conseil Scientifique du Centre Franois Baclesse, Esch/Alzette - PrsidentEuropean Society of Medical Oncology (ESMO)American Society of Clinical Oncology (ASCO)Socit Luxembourgeoise dOncologie (SLO)Fondation de Recherche Cancer et SangFondation contre le Cancer

  • A

    ctiv

    its

    scie

    ntifi

    ques

    et a

    cad

    miq

    ues

    au C

    HL

    par

    serv

    ices

    17

    CANCROLOGIE I HMATOLOGIE 2012-2013 / 2

    Communication un Congrs / Runion Scientifique

    G Berchem : Integration of medical research in clinical practive: the Luxembourg Lung Cancer Study. (Forward look at ways to improve the quality of clinical research linked with medical practice).4me Journe de la Recherche Clinique, CRP-Sant, Novotel Kirchberg. 24.10.12

    G Berchem : Quelles analyses molculaires tumorales ralises aujourdhui en routine pour les traite-ments de demain? Symposium pluridisciplinaire dautomne en oncologie thoracique. Cercle de Wallonie, Namur, 26.10.2012

    G Berchem : Un nouvel outil dinformation pour les patients. 1er SLO CANCER UPDATE FORUM : Ap-proche multi-disciplinaire du cancer de la prostate.Universit de Luxembourg, Campus Limpertsberg. 24.11.2012

    G Berchem : Autophagy and cancer: death for survival? Cancer Research and TELEVIE: The progress in 25 years? TELEVIEs Researchers Seminar, 10.12.2012

    G Berchem : Aspects pratiques sur le testing EML-ALK au Luxembourg. ALK a new target in Non-Small Cell Lung Cancer. Socit Luxembourgeoise de Pneumologie/Socit Luxembourgeoise dOncologie. Chambre du Com-merce. 19.12.2012

    G Berchem : Management of brain tumor patients in Luxembourg: medical treatment and radiothrapie.CRP-Sant Neuro-Oncology Workshop. CHL. 08.03.2013.

    G Berchem : 2013 Lung Cancer Conference. Lung Cancer Treatment in the Era of Personalised Medicine.Scientific Organising Committee. Novotel. Luxembourg, 14.15.03.2013.

    G Berchem : Update sur les traitements mdicamenteux. 2me SLO Cancer Update Forum. Cancer du poumon : du dpistage au traitement palliatif.Universit de Luxembourg, Kirchberg, 16.03.2013.

    G Berchem : Prsentation of Luxembourgs Personalized Medicine Initiative.Labatt Brain Tumor Research Centre. Toronto (CA) 9.05.2013.

    G Berchem : Pharmacogenomics and Biomarkers in medical oncology: Lung Cancer Pharmacogenomics: From Cell to Clinic. European Society of Pharmacogenomics and Theranostics Se-cond Conference, Lisbon (P) 26.09.2013

    G Berchem : EUSTM-2013 Personalized Medicine in Oncology, chairman.CRP-Sant, Hotel Novotel Kirchberg, 23/10/2013

    G Berchem : - Les tumeurs crbrales primitives. - Traitements systmiquesSymposium de Formation. Groupes Soignants en Oncologie.CHL. 16.11.2013

  • A

    ctiv

    its

    scie

    ntifi

    ques

    et a

    cad

    miq

    ues

    au C

    HL

    par

    serv

    ices

    18

    CANCROLOGIE I HMATOLOGIE 2012-2013 / 3

    G Berchem : Non-Small Cell Lung Cancer (non-squamous).7th Belgian Symposium on the Integration of Molecular Biology Advances into Oncology Clinical Prac-tice. Diegen (B), 23.11.13

    G Berchem : La rsistance aux antibiotiques: la recherche de solutions locales pour un dfi global. Confrence-Dbat.CHL, 11.12.2013.

    M Dicato : Forward look at ways to improve the quality of clinical research linked with medical practice. Session introduction.4me Journe de la Recherche Clinique, CRP-Sant, Novotel Kirchberg. 24.10.12

    B. Metzger, M Dicato, G. Mahon, S. Obertin, J. Kayser : Mutation of either RAS or BRAF correlates with MGMT methylation and mutation of PIK with PTEN methylation, but non of these is associated with stage in colorectal cancer, 37th ESMO Congress 2012, Vienna, 28.09.2012.

    M Dicato : Ce quil faut savoir sur les nouveaux anticoagulantsLes actualits en mdecine et chirurgie. Uni.Lu, Auditoire BS 0.03, Alformec, 12.01.2013

    Nouveauts en Mnopause, Prsident Dr M. Peiffer, Modrateur Dr M DicatoInternational Symposium Well Aging, Andropause/MenopauseSofitel Kirchberg, SLAM, 14-15.06.13.

    C Duhem : Les effets secondaires long terme des traitements anticancreux.Les actualits en mdecine et chirurgie. Uni.Lu, Auditoire BS 0.03, Alformec, 12.01.2013

    C Duhem : Risque de cancer aprs PMA. Impact de la stimulation ovarienne. Risques chez les enfants issus de la PMA. Cancer, Fertilit et grossesse? Journe de la PMA : Avoir un enfant aprs cancer: est-ce possible?Amphi CHL 19.10.13.

    C Duhem : Les mtastases crbrales : incidence et principes de traitements.Tumeurs crbrales quand le flou sinstalle. CHL Amphi. 16.11.13.

    L Plawny : Syndrome mylodysplasiques, de lattitude attentiste vers une prise en charge mdicamen-teuse, Les actualits en mdecine et chirurgie.Uni.Lu, Auditoire BS 0.03, Alformec, 12.01.2013

    S Serban Stefan, L Plawny : Clofarabine in bad prognosis acute myeloid leukaemia, 27th meeting of the Belgian Haematological society. Lige (B) 27.-28.01.12 L Duquenne, L Plawny : Spontaneous intraocular bleeding as an initial presentation of factor XI defi-ciency. 27th meeting of the Belgian Haematological society. Lige.(B) 27.-28.01.12

  • A

    ctiv

    its

    scie

    ntifi

    ques

    et a

    cad

    miq

    ues

    au C

    HL

    par

    serv

    ices

    19

    CANCROLOGIE I HMATOLOGIE 2012-2013 / 4

    A Diciolla, L Plawny : Acquired Haemophilia, 27th meeting of the Belgian Haematological society. Lige.(B) 27.-28.01.12

    AV Schettini, L Plawny : Cerebrospinal fluid invasion in an APL patient. A case report, Belgian Haema-tological Society, 2013

    N Nemeti Baicu, L Plawny : Rituximab as a maintenance treatment in thrombotic thrombocytopenic purpura : a case report, Belgian Haematological Society, 2013

    Ludovicy S, Charpentier A., Chalabi K., Graux C. PhD, Plawny L. Large pericardial effusion after hetero-logous stem cell transplant : about two cases, Belgian Haematological Society, 2013

    Publications scientifiques

    Noman MZ, Janji B, Berchem G, Mami-Chouaib F, Chouaib S. Hypoxia-induced autophagy : a new player in cancer immunotherapy? Autophagy. 2012 Apr. 8 (4):704-6. (Facteur dimpact 2012: 12.042)

    Sawadogo WR, Schumacher M, Teiten MH, Dicato M, Diederich M. Traditional West African pharma-copeia, plants and derived compounds for cancer therapy.BiochemPharmacol. 2012 Nov 15 ; 84(10):1225-40. (Facteur dimpact 2012: 4.576)

    Kelkel M, Cerella C, Mack F, Schneider T, Jacob C, Schumacher M, Dicato M, Diederich M. ROS-inde-pendent JNK activation and multisite phosphorylation of Bcl-2 link diallyl tetrasulfide-induced mitotic arrest to apoptosis.Carcinogenesis. 2012 Nov;33(11):2162-71. (Facteur dimpact 2012: 5.635)

    Seidel C, Florean C, Schnekenburger M, Dicato M, Diederich M. Chromatin-modifying agents in anti-cancer therapy.Biochimie. 2012Nov;94(11):2264-79. (Facteur dimpact 2012: 3.142)

    Folmer F, Dicato M, Diederich M. From the deepest sea shelf to the uppermost kitchen cabinet shelf: the quest for novel TNF- inhibitors.Curr Top Med Chem.2012;12(13):1392-407. (Facteur dimpact 2012: 3.702)

  • A

    ctiv

    its

    scie

    ntifi

    ques

    et a

    cad

    miq

    ues

    au C

    HL

    par

    serv

    ices

    20

    CANCROLOGIE I HMATOLOGIE 2012-2013 / 5

    Teiten MH, Gaigneaux A, Chateauvieux S, Billing AM, Planchon S, Fack F, Renaut J, Mack F, Muller CP, Dicato M, Diederich M ; Identification of differentially expressed proteins in curcumin-treated prostate cancer cell lines.OMICS. 2012 Jun; 16(6):289-300. (Facteur dimpact 2012: 2.730)

    B. Metzger, M A Dicato, G. Mahon, S. Obertin, J. Kayser ; Mutation of either RAS or BRAF correlates with MGMT methylation and mutation of PIK with PTEN methylation, but non of these is associated with stage in colorectal cancer.Annals Of Oncology, Sept 2012, 23/9, 186-187. (Facteur dimpact 2012: 7.384)

    Pauly M, Mahon G, M A Dicato, Metzger B, Menzel A ; Single nucleotide polymorphisms (SNPS) in the P53, SMAD7 and TGFBRI genes associated with advances colorectal cancer in Caucasian patient com-pared to healthy controls.Annals Of Oncology, Sept 2012, 23/9, 209-209. (Facteur dimpact 2012: 7.384)

    Aapro M, Molassiotis A, Dicato M, Pelez I, Rodrguez-Lescure , Pastorelli D, Ma L, Burke T, Gu A, Gascon P, Roila F; PEER investigators. The effect of guideline-consistent antiemetic therapy on chemo-therapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER).Ann Oncol. 2012 Aug;23(8):1986-92. (Facteur dimpact 2012: 7.384)

    Karius T, Schnekenburger M, Dicato M, Diederich M. MicroRNAs in cancer management and their modu-lation by dietary agents.Biochem Pharmacol. 2012 Jun 15;83(12):1591-601. (Facteur dimpact 2012: 4.576)

    Seidel C, Schnekenburger M, Dicato M, Diederich M. Histone deacetylase modulators provided by Mo-ther Nature.Genes Nutr. 2012 Jul;7(3):357-67. (Facteur dimpact 2012: 3.329)

    Trcul A, Morceau F, Dicato M, Diederich M. Dietary compounds as potent inhibitors of the signal trans-ducers and activators of transcription (STAT) 3 regulatory network.Genes Nutr. 2012 Apr;7(2):111-25. (Facteur dimpact 2012: 3.329)

    Mieog JS, Morden JP, Bliss JM, Coombes RC, van de Velde CJ;Dicato M. IES Steering Committee. Carpal tunnel syndrome and musculoskeletal symptoms in postmenopausal women with early breast cancer treated with exemestane or tamoxifen after 2-3 years of tamoxifen: a retrospective analysis of the Intergroup Exemestane Study.Lancet Oncol. 2012 Apr;13(4):420-32. (Facteur dimpact 2012: 25.117)

    Dicato M Thrombosis in Cancer Patients.Ann Oncol. 2012 Sept; 23 (9): 56. (Facteur dimpact 2012: 7.384)

    Dicato M Biosimilars: Is absence of proof of difference, proof of absence of difference? Target Oncol. 2012 Mar;7 Suppl 1:S1-2. (Facteur dimpact 2012: 2.764)

  • A

    ctiv

    its

    scie

    ntifi

    ques

    et a

    cad

    miq

    ues

    au C

    HL

    par

    serv

    ices

    21

    CANCROLOGIE I HMATOLOGIE 2012-2013 / 6

    Schumacher M, Dicato M,Diederich M, NK-kappa B Inhibitors from Terrestrial Plants Reported in 2011.Journal of Food and Drug Analysis, April 2012.20 (1), 250-259. (Facteur dimpact 2012: 0.333)

    Teiten MH, Gaascht F, Dicato M, Diederich M. Targeting the Wingless Signaling Pathway with Natural Coumpounds as Chemopreventive or Chemotherapeutic Agents.Current Pharmaceutical Biotechnology 2012 Jan;13(1):245-254. (Facteur dimpact 2012: 2.690)

    Dicato M, Plawny L. Nouveaux anticoagulants : ont-ils dj une place en oncologie ?Oncologie 2012, 14:659-662 (Facteur dimpact 2012: 0.097)

    Plawny L: Point of view about new guidelines on ESAs (erythropoiesis-stimulating agents)Belgian Journal of Hematology 2012; 3: 88-94

    Dicato M (Livre) : Side Effects of Medical Cancer TherapyPrevention and Treatment

    Viry E, Baginska J, Berchem G, Noman MZ, Medves S, Chouaib S, Janji B. Autophagic degradation of GZMB/granzyme B: A new mechanism of hypoxic tumor cell escape from natural killer cell-mediated lysis.Autophagy. Epub 2013 Nov 15. Facteur dimpact: 12.042

    Baginska J, Viry E, Berchem G, Poli A, Noman MZ, van Moer K, Medves S, Zimmer J, Oudin A, Niclou SP, Bleackley RC, Goping IS, Chouaib S, Janji B. Granzyme B degradation by autophagy decreases tumor cell susceptibility to naturalkiller-mediated lysis under hypoxia. Proc Natl Acad Sci U S A. 2013 Oct22; 110(43):17450-5. Facteur dimpact 2012: 9.737

    Paggetti J, Berchem G, Moussay E. Stromal cell-induced miRNA alteration in chronic lymphocytic leuke-mia: how a minute and unavoidable cell contamination impairs miRNA profiling.Leukemia. 2013 Aug;27(8):1773-6. Facteur dimpact 2012: 10.164

    Gbler K, Rolvering C, Kaczor J, Eulenfeld R, Mndez S, Berchem G, Palissot V, Behrmann I, Haan C. Cooperative effects of Janus and Aurora kinase inhibition by CEP701 in cells expressing Jak2V617F.J Cell Mol Med. 2013 Feb;17(2):265-76. Facteur dimpact 2012: 4.753

    Bana E, Sibille E, Valente S, Cerella C, Chaimbault P, Kirsch G, Dicato M, Diederich M, Bagrel D. A novel coumarin-quinone derivative SV37 inhibits CDC25 phosphatases, impairs proliferation, and induces cell death. Mol Carcinog. 2013 Oct 24. Facteur dimpact 2012: 4.269

    Molassiotis A, Aapro M, Dicato M, Gascon P, Novoa SA, Isambert N, Burke TA, Gu A, Roila F. Evaluation of Risk Factors Predicting Chemotherapy-Related Nausea and Vomiting: Results From a European Pros-pective Observational Study. J Pain Symptom Manage. 2013 Sep 24. Facteur dmpact 2012: 2.601

  • A

    ctiv

    its

    scie

    ntifi

    ques

    et a

    cad

    miq

    ues

    au C

    HL

    par

    serv

    ices

    22

    CANCROLOGIE I HMATOLOGIE 2012-2013 / 7

    Teiten MH, Gaascht F, Dicato M, Diederich M. Anticancer bioactivity of compounds from medicinal plants used in European medieval traditions. Biochem Pharmacol. 2013 Nov 1;86(9):1239-47. Facteur dimpact 2012: 4.576

    Morceau F, Chateauvieux S, Gaigneaux A, Dicato M, Diederich M. Long and short non-coding RNAs as regulators of hematopoietic differentiation. Int J Mol Sci. 2013 Jul 15;14(7):14744-70. Facteur dimpact 2012 2.464

    Orlikova B, Schumacher M, Juncker T, Yan CC, Inayat-Hussain SH, Hajjouli S, Cerella C, Dicato M, Die-derich M. Styryl-lactone goniothalamin inhibits TNF--induced NF-B activation. Food Chem Toxicol. 2013 Sep;59:572-8. Facteur dImpact 2012: 3.010

    Trcul A, Morceau F, Gaigneaux A, Orsini M, Chateauvieux S, Grandjenette C, Dicato M, Diederich M. Polyphenol tri-vanillic ester 13c inhibits P-JAK2V617F and Bcr-Abl oncokinase expression in correlation with STAT3/STAT5 inactivation and apoptosis induction in human leukemia cells.Cancer Lett. 2013 Oct 28;340(1):30-42. Facteur dImpact 2012: 4.258

    Cerella C, Dicato M, Diederich M. Assembling the puzzle of anti-cancer mechanisms triggered by cardiac glycosides.Mitochondrion. 2013 May;13(3):225-34. Facteur dImpact 2012: 4.025

    Teiten MH, Dicato M, Diederich M. Curcumin as a regulator of epigenetic events.Mol Nutr Food Res. 2013 Sep;57(9):1619-29. Facteur dImpact 2012: 4.310

    Teiten MH, Mack F, Debbab A, Aly AH, Dicato M, Proksch P, Diederich M. Anticancer effect of altersola-nol A, a metabolite produced by the endophytic fungus Stemphylium globuliferum, mediated by its pro-apoptotic and anti-invasive potential via the inhibition of NF-B activity. Bioorg Med Chem. 2013 Jul 1;21(13):3850-8. Facteur dImpact 2012: 2.338

    Sawadogo WR, Schumacher M, Teiten MH, Cerella C, Dicato M, Diederich M. A survey of marine natural compounds and their derivatives with anti-cancer activity reported in 2011. Molecules. 2013 Mar 25;18(4):3641-73. Facteur dImpact 2012: 2.428

    Godino C, Lauretta L, Pavon AG, Mangieri A, Viani G, Chieffo A, Galaverna S, Latib A, Montorfano M, Cap-pelletti A, Maisano F, Alfieri O, Margonato A, Colombo A. Heydes syndrome incidence and outcome in patients undergoing transcatheter aortic valve implantation. J Am Coll Cardiol. 2013 Feb 12;61(6):687-9. Facteur dImpact 2012: 14.086

    Baginska J, Viry E, Paggetti J, Medves S, Berchem G, Moussay E, Janji B. The Critical Role of the Tumor Microenvironment in Shaping Natural Killer Cell-Mediated Anti-Tumor Immunity. Front Immunol. 2013 Dec 25;4:490.

    Calteux N, Berchem G, Schmid N, Nebendahl J, Fischer G. Giant melanoma of the scalp: Case report]. Bull Soc Sci Med Grand Duche Luxemb. 2013;(1):40-6.

  • A

    ctiv

    its

    scie

    ntifi

    ques

    et a

    cad

    miq

    ues

    au C

    HL

    par

    serv

    ices

    23

    CANCROLOGIE I HMATOLOGIE 2012-2013 / 8

    Gaascht F, Dicato M, Diederich M. Venus Flytrap (Dionaea muscipula Solander ex Ellis) Contains Power-ful Compounds that Prevent and Cure Cancer. Front Oncol.2013 Aug 20;3:202.

    Cerella C, Radogna F, Dicato M, Diederich M. Natural compounds as regulators of the cancer cell meta-bolism. Int J Cell Biol. 2013;2013:639401.

    Lauretta L, Dagna L, Alberti L, Loiacono F, De Cobelli F, Sanvito F, Moriggia S, Margonato A, Fragasso G. Cardiovascular involvement in Erdheim-Chester syndrome: clinical and therapeutic implications.Recenti Prog Med. 2013 Dec;104(12):637-42.

    Alberti L, Torlasco C, Lauretta L, Loffi M, Maranta F, Salonia A, Margonato A, Montorsi F, Fragasso G. Erectile dysfunction in heart failure patients: a critical reappraisal.Andrology. 2013 Mar;1(2):177-91.

    Sofos S, Azagra JS, Arru L, Ries F, Leider P, Weber J, Goergen M. Multidisciplinary management of a gastric metastasis of uveal melanoma presenting 12 years after enucleation. Bull Soc Sci Med Grand Duche Luxemb. 2013;(2):63-8.

    Warling O, Guiot J, Ramaut M, Servais A, Lewin M, Louis R. [Clinical case of the month. Idiopathic me-diastinal fibrosis].Rev Med Liege. 2013 Jul-Aug;68(7-8):408-11.

    Etudes en cours

    ARANESP : Etude randomise, en double aveugle, contrle contre placebo, valuant lefficacit et la s-curit long terme de la darbepoetin alfa administre la dose de 500ug une fois toutes les 3 semaines chez des sujets anmiques souffrant dun cancer du poumon non--petites cellules de stade avanc et recevant plusieurs cycles de chimiothrapie. Dr G BerchemSponsor : Amgen

    BREC (2012): Multicentre, phase 3, randomized study to evaluate treatment customized according to rap80 and brca 1 assessment in patients with advances non-small-cell lung cancer. Dr G Berchem Sponsor : SLCG

    CAMN107 : Multicenter, phase IIIb, open-label study, nilotinib treatment in adult-patients with a recent diagnosis of chronic myeloid leukemia in chronic phase (LMC PC), positive for Philadelphia chromosome (Ph+) and/or Bc+. Dr C Duhem Sponsor : Novartis

    FIELT : Prospective Evaluation of Small Molecule EGFR-1 Tyrosine Kinase Inhibition as a First-Line Treatment in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Harbouring a Mutant EGFR Gene. Dr G Berchem,Sponsor : AZ-VUB

  • A

    ctiv

    its

    scie

    ntifi

    ques

    et a

    cad

    miq

    ues

    au C

    HL

    par

    serv

    ices

    24

    HPN-Registry. Registre Hmoglobinurie paroxystique nocturne. Dpartement dHmatologie-Cancrologie. Dr S De Wilde Sponsor : Alexion

    JUMP : An open-label, multicenter, expanded access study of INC424 for patients with primary mylo-fibrosis (PMF) or post polycythmie myelofibrosis (PPV-MF) or postessential thrombocythemia myelo-fibrosis (PET-MF). Dr S De Wilde Sponsor : Novartis

    LAPATINIB-EGF : An Open-Label Expanded Access Study of Lapatinib and Capecitabine Therapy in Sub-jects with ErbB2 Over-expressing Locally Advanced or Metastatic Breast Cancer.Dpartement dHmatologie-Cancrologie. Dr C Duhem Sponsor : Glaxo-Smith-Kline

    LCS : Biomarker Discovery and Validation in Lung Cancer. Dr G Berchem, Dr M. SchlesserIntegrated Biobank of Luxembourg (IBBL) 37 inclusions

    MO28231 : Etude multicentrique, un seul bras sur TRASTUZUMAB EMTANSINE (T-DM1) chez des patients atteints de cancer du sein HER2 positif. Localement avanc ou mtastatique, qui ont pralale-ment reu un traitement anti-HER2 et une chimiothrapie. Dr C Duhem Sponsor : Roche

    NP28673/Accalia : An open-label, non-randomized multicenter phase I/II trial of RO5424802 given orally to non-small cell lung cancer patients who have ALK mutation and failed CRIZOTINIB treatment. Dr C Berchem Sponsor : Roche

    PASS : A non-interventional observational post authorisation safety study of subjects treated with lena-lidomide Dr G BerchemSponsor : Celgene

    PATSGO : Etude multicentrique de phase II comparant la prise, en situation adjuvante, de Temozolomide (tmz) de facon prolongee a un schema du TMZ chez les patients atteints dun glioblas-tome. Dr G BerchemCliniques Universitaires St Luc

    PCA3: A prospective pilot study on the feasability and clinical evaluation on the PCA3 test in male uro-logy patients in Luxembourg, with constitution of a prostate cancer sample collectionDr G Berchem, Dr M. SchlesserIntegrated Biobank of Luxembourg (IBBL)

    CANCROLOGIE I HMATOLOGIE 2012-2013 / 9

  • A

    ctiv

    its

    scie

    ntifi

    ques

    et a

    cad

    miq

    ues

    au C

    HL

    par

    serv

    ices

    25

    CANCROLOGIE I HMATOLOGIE 2012-2013 / 10

    PROFILE : Phase 3, randomized, open-label study of the efficacy and safety of crizotinib versus pemet-rexed/cisplatin or pemetrexed/carboplastin in previously untreated patients with non-squamous carci-noma of the lung harboring a translocation or inversion event involving the anaplastic lymphoma kinase (alk) gene locus. Dr G Berchem Sponsor : PFIZER (Quintiles)

    PROTECT : A Randomized, Double-blind, Placebo-controlled phase III study to evaluate the efficacy and safety of pazopanib as adjuvant therapy for subjects with localized or locally advanced RCC following nephrectomy. Dr G BerchemSponsor : Glaxo-Smith-Kline

    Prostate Cancer Registry. A prospective registry of patients with a confirmed diagnosis of adenomacar-cinoma of the prostate prs. Dr G BerchemSponsor : Janssen-Cilag

    RAD-BOLERO3 (2012) : A randomized Phase III, double-blind, placebo-controlledmulticenter trial of daily everolimus in combination with trastuzumab and vinorelbine, in pretreated women with HER2/neu over-expressing locally advanced or metastatic breast cancer. (stoppe en 2012). Dr C Duhem Sponsor : Novartis

  • A

    ctiv

    its

    scie

    ntifi

    ques

    et a

    cad

    miq

    ues

    au C

    HL

    par

    serv

    ices

    26

    CARDIOLOGIE I MALADIES VASCULAIRES 2012-2013 / 1

    CARDIOLOGIE ET MALADIES VASCULAIRES

    Appartenance une Socit Scientifique

    J Beissel : European Society of Cardiology (ESC)Socit Franaise de Cardiologie (SFC)European Association of Percutaneous Cardiovascular Interventions (EAPCI)Socit Luxembourgeoise de Cardiologie - PrsidentLuxembourg Ressuscitation Council - vice-Prsident, Membre Fondateur

    C Delagardelle : German Society of Cardiology Society of Sports Medicine of Luxembourg - head, chairmanAnti-Doping Agency of LuxembourgAmerican Society of Nuclear Cardiology European Society of Cardiac Rehabilitation and PreventionOlympic committee of Luxembourg - honorary memberSociety of Cardiology of Luxembourg Association Francophone de Prvention et de Radaptation Cardiaque - directory board Groupe de travail Alimentation et Activits physiques Conseil National Scientifique Groupe de Travail Risques cardio-vasculaires - conseiller externeCardiologue Investigateur de ltude ORISCAVCardiologue Investigateur de ltude NESCAV

    D Wagner :American College of Cardiology (FACC)European Society of Cardiology (FESC)American Heart Association (AHA)Deutschen Gesellschaft fr Kardiologie (DGK)

    Communication un Congrs / Runion scientifique

    Ch Delagardelle : La Socit Luxembourgeoise de Mdecine du Sport (SLMS) a 60 ans. Bulletin de la Socit des Sciences Mdicales. Janvier 2012

    Ch Delagardelle : Congrs EuroPRevent 2012, Dublin (IR), 03.-05.05.12

    P Feiereisen, M Vaillant, Ch Delagardelle : Cardiopulmonary impact of resistance training in chronic heart failure. Prevention and Epidemiology. Congrs EuroPRevent 2012, Dublin (IR), 03.-05.05.12

    C Delagardelle : Sportherz 2012, 7me Atelier mdico-sportif, aspect mdico-sportifs dans le cyclism. Centre National Sportif et Culturel dCoque. 15.12.12

  • A

    ctiv

    its

    scie

    ntifi

    ques

    et a

    cad

    miq

    ues

    au C

    HL

    par

    serv

    ices

    27

    CARDIOLOGIE I MALADIES VASCULAIRES 2012-2013 / 2

    J Beissel : Modration et Conclusion.Cardiologie 2013 des guidelines la pratique, Cercle Cit, Alformec, 02.02.13,

    C Delagardelle : Prvention : nouveaux messages cls.Cardiologie 2013 des guidelines la pratique, Cercle Cit, Alformec, 02.02.13,

    S Noppe : Insuffisance cardiaque : traitement et cogestionCardiologie 2013 des guidelines la pratique, Cercle Cit, Alformec, 02.02.13,

    D Wagner : Tabagisme et impact sur la sant : Aspects cardiovasculaires.Sevrage tabagique en mdecine gnrale, comment relever le dfi au quotidien?Chambre de Commerce Luxembourg, 19.01.13

    D Wagner Valvulopathies : Heart team et rle des nouvelles techniques, Cardiologie 2013 des guidelines la pratique, Cercle Cit, Alformec, 02.02.13,

    D Wagner Translational Research : Updates in Pathophysiologie, Chairman.EUSTM-2013, Hotel Novotel Kirchberg, CRP-Sant, 23.10.13

    D Wagner Die Rolle des Kardiologen beim SchlaganfallUpdate Schlaganfall, Amphi CHL, 15.06.13

    Applications des guidelines aux cas cliniques de la vie quotidienne, Dr C Pesch, Dr C. Dimmer, Dr Y. Ernst, Dr L Groben, Dr C. AcasandreiXVIe Colloque Luxembourgeois de Rythmologie, Coque Kirchberg,13.11.13,

    Publications

    Tchicaya A, Braun M, Lorentz N, Delagardelle C, Beissel J, Wagner DR. Social inequality in awareness of cardiovascular risk factors in patients undergoing coronary angiography.Eur J Prev Cardiol. 2012 Apr 16. (Facteur dimpact 2012: 3.903)

    Alkerwi A, Sauvageot N, Pagny S, Beissel J, Delagardelle C, Lair ML. Acculturation, immigration status and cardiovascular risk factors amongPortuguese immigrants to Luxembourg: findings from ORISCAV-LUX study. BMC Public Health. 2012 Oct 11 ; 12:864. (Facteur dimpact 2012: 2.076)

    Martins RP, Blangy H, Muresan L, Freysz L, Groben L, Zinzius PY, Schwartz J, Sellal JM, Aliot E, Sadoul N. Safety and efficacy of programming a high number of antitachycardia pacing attempts for fast ventri-cular tachycardia: a prospective study. Europace. 2012 Oct ; 14(10) : 1457-64 (Facteur dimpact 2012: 2.765)

    De Chillou C, Magnin-Poull I, Andronache M, Sacher F, Groben L, Abdelaal A, Muresan L, Jarmouni S, Schwartz J, Jas P, Aliot E. Showing up channels for postinfarct ventricular tachycardia ablation.Pacing Clin Electrophysiol. 2012 Jul ; 35(7):897-904. (Facteur dimpact 2012: 1.746)

  • A

    ctiv

    its

    scie

    ntifi

    ques

    et a

    cad

    miq

    ues

    au C

    HL

    par

    serv

    ices

    28

    CARDIOLOGIE I MALADIES VASCULAIRES 2012-2013 / 3

    Laporte F, Olivier A, Groben L, Admant P, Aliot E. Aortocaval fistula: an uncommon cause of paradoxical embolism.J Cardiovasc Med (Hagerstown). 2012 Jan ; 13(1):68-71. (Facteur dimpact 2012: 2.657)

    Selton-Suty C, Clard M, Le Moing V, Doco-Lecompte T, Chirouze C, Iung B, Strady C, Revest M, Vande-nesch F, Bouvet A, Delahaye F, Alla F, Duval X, Hoen B; Groben L.. AEPEI Study Group. Preeminence of Staphylococcus aureus in infective endocarditis: a 1-year population-based survey.Clin Infect Dis. 2012 May ; 54(9) : 1230-9. (Facteur dimpact 2012: 9.374)

    Martinez C, Maazoun Y, Durieux R, Defraigne J, Legrand V. Endovascular repair of the left subclavian artery after gunshot wound: an alternative to surgical treatment.Acta Cardiol. 2012 Oct;67(5):609-12. (Facteur dimpact 2012: 0.607)

    Maazoun Y, Martinez C, Radermecker M, Magne J, Durieux R, Gach O, Davin L, Defraigne J, Legrand V, . Incidence, predictive factors and prognostic value of inflammatory reaction following transcatheter aortic valve implantation (TAVI).European Heart Journal. 2012 Aug; 33(1): 718-718. (Facteur dimpact 2012: 14.097)

    Stammet P, Goretti E, Vausort M, Zhang L, Wagner DR, Devaux Y. Circulating microRNAs after cardiac arrest.Crit Care Med. 2012 Dec; 40(12): 3209-14. (Facteur dimpact 2012: 6.124)

    Azuaje FJ, Dewey FE, Brutsaert DL, Devaux Y, Ashley EA, Wagner DR. Systems-based approaches to cardiovascular biomarker discovery.Circ Cardiovasc Genet. 2012 Jun; 5(3): 360-7. (Facteur dimpact 2012: 6.728)

    Bousquenaud M, Schwartz C, Lonard F, Rolland-Turner M, Wagner D, Devaux Y. Monocyte chemotactic protein 3 is a homing factor for circulating angiogenic cells.Cardiovasc Res. 2012 Jun 1; 94(3): 519-25. (Facteur dimpact 2012: 5.940)

    Devaux Y, Vausort M, Azuaje F, Vaillant M, Lair ML, Gayat E, Lassus J, Ng LL, Kelly D, Wagner DR, Squire IB. Low levels of vascular endothelial growth factor B predict left ventricular remodeling after acute myocardial infarction.J Card Fail. 2012 Apr; 18(4): 330-7. (Facteur dimpact 2012: 3.320)

    Emilian C, Goretti E, Prospert F, Pouthier D, Duhoux P, Gilson G, Devaux Y, Wagner DR. MicroRNAs in patients on chronic hemodialysis (MINOS study).Clin J Am Soc Nephrol. 2012 Apr; 7(4): 619-23. (Facteur dimpact 2012: 5.068)

    Bousquenaud M, Maskali F, Poussier S, Marie PY, Boutley H, Karcher G, Wagner DR, Devaux Y. Acipi-mox-enhanced 18F-fluorodeoxyglucose positron emission tomography for characterizing and predicting early remodeling in the rat infarct model.Int J Cardiovasc Imaging. 2012 Aug; 28(6): 1407-15 (Facteur dimpact 2012: 2.648)

    Azuaje FJ, Devaux Y, Wagner DR. Prediction of adverse cardiovascular events of noncardiovascular drugs through drug-target interaction networks.Clin Transl Sci. 2012 Feb; 5(1): 111. (Facteur dimpact 2012: 2.330)

  • A

    ctiv

    its

    scie

    ntifi

    ques

    et a

    cad

    miq

    ues

    au C

    HL

    par

    serv

    ices

    29

    CARDIOLOGIE I MALADIES VASCULAIRES 2012-2013 / 4

    Devaux Y, Vausort M, Goretti E, Nazarov PV, Azuaje F, Gilson G, Corsten MF, Schroen B, Lair ML, Hey-mans S, Wagner DR, Use of Circulating Micro RNAs to Diagnose Acute Myocardial Infarction.Clinical Chemistry 2012 Mar, 58 (3): 559-567. (Facteur dimpact 2012: 7.149)

    Delagardelle C [The Luxembourg Society for Sports Medicine (SLM) after 60 years].Bull Soc Sci Med Grand Duche Luxemb. 2012; (1): 50-9

    Chapitres de livre : Delagardelle C, Lencadrement mdical et kinsithrapeutique des slections luxem-bourgeoises aux Jeux OlympiquesDans le livre blanc .100 ANS DOLYMPISME AU LUXEMBOURG 1912-1012 (2012, P.241-243)

    Alkerwi A, Pagny S, Lair ML, Delagardelle C, Beissel J. Level of unawareness and management of dia-betes, hypertension, and dyslipidemia among adults in Luxembourg: findings from ORISCAV-LUX study.PLoS One. 2013; 8(3):e57920. Facteur dimpact 2012: 3.730

    Feiereisen P, Vaillant M, Gilson G, Delagardelle C. Effects of different training modalities on circulating anabolic/catabolic markers in chronic heart failure.J Cardiopulm Rehabil Prev. 2013 Sep-Oct; 33(5): 303-8. Facteur dimpact 2012: 1.585

    Rolland-Turner M, Goretti E, Bousquenaud M, Lonard F, Nicolas C, Zhang L, Maskali F. Marie P.Y., Devaux Y, Wagner D. Adenosine Stimulates the Migration of Human Endothelial Progenitor Cells. Role ofCXCR4 and MicroRNA-150.PLoS ONE2013; 8(1): e54135. Facteur dimpact 2012: 3.730

    Devaux Y, Mueller M, Haaf P, Goretti E, Twerenbold R, Zangrando J, Vausort M, Reichlin T, Wildi K, Moehring B, Wagner DR, Mueller C. Diagnostic and prognostic value of circulating microRNAs in pa-tients with acute chest pain.J Intern Med. 2013 Dec 17. Facteur dimpact 2012: 6.455

    Goretti E, Wagner DR Devaux Y. Regulation of endothelial progenitor cell function by micrornas.Minerva Cardioangiol. 2013 Dec; 61(6): 591-604. Facteur dimpact 2012: 0.427

    Devaux Y, Vausort M, McCann GP, Kelly D, Collignon O, Ng LL, Wagner DR Squire IB. Correction: A Panel of 4 microRNAs Facilitates the Prediction of Left Ventricular Contractility after Acute Myocardial Infarction.PLoS One. 2013 Aug 23; 8(8). Facteur dimpact 2012: 3.730

    Bousquenaud M, Maskali F, Poussier S, Zangrando J, Marie PY, Boutley H, Fay R, Karcher G, Wagner DR Devaux Y. Cardioprotective effects of adenosine within the border and remote areas of myocardial infarction.EJNMMI Res. 2013 Sep 12; 3(1): 65. Facteur dimpact 2012: 5.114

    Devaux Y, Vausort M, McCann GP, Kelly D, Collignon O, Ng LL, Wagner DR, Squire IB. A panel of 4 microRNAs facilitates the prediction of left ventricular contractility after acute myocardial infarction.PLoS One. 2013 Aug 13; 8(8): e70644. Facteur dimpact 2012: 3.730

    Devaux Y, McCann GP, Wagner DR, Squire IB. Prognostic microRNAs after AMI.Circ Res. 2013 Aug 16; 113(5):e46-7. Facteur dimpact 2012: 11.861

  • A

    ctiv

    its

    scie

    ntifi

    ques

    et a

    cad

    miq

    ues

    au C

    HL

    par

    serv

    ices

    30

    CARDIOLOGIE I MALADIES VASCULAIRES 2012-2013 / 5

    Goretti E, Vausort M, Wagner DR, Devaux Y. Association between circulating microRNAs, cardiovascular risk factors and outcome in patients with acute myocardial infarction.Int J Cardiol. 2013 Oct 9; 168(4): 4548-50. Facteur dimpact 2012: 5.509

    Azuaje F, Zhang L, Jeanty C, Puhl SL, Rodius S, Wagner DR Analysis of a gene co-expression network establishes robust association between Col5a2 and ischemic heart disease.BMC Med Genomics. 2013 Apr 10; 6:13. Facteur dimpact 2012: 3.466

    Devaux Y, Vausort M, McCann GP, Zangrando J, Kelly D, Razvi N, Zhang L, Ng LL, Wagner DR Squire IB. MicroRNA-150: a novel marker of left ventricular remodeling after acute myocardial infarction.Circ Cardiovasc Genet. 2013 Jun; 6(3):290-8. Facteur dimpact 2012: 6.728

    Goretti E, Rolland-Turner M, Lonard F, Zhang L, Wagner DR, Devaux Y. MicroRNA-16 affects key func-tions of human endothelial progenitor cells.J Leukoc Biol. 2013 May; 93(5): 645-55. Facteur dimpact 2012: 4.568

    Stammet P, Wagner DR, Gilson G, Devaux Y. Modeling serum level of s100 and bispectral index to pre-dict outcome after cardiac arrest. J Am Coll Cardiol. 2013, Aug 27; 62(9): 851-8. Facteur dimpact 2012: 14.086

    Metallidis S, Tsachouridou O, Skoura L, Zebekakis P, Chrysanthidis T, Pilalas D, Bakaimi I, Kollaras P, Germanidis G, Tsiara A, Galanos A, Malisiovas N, Nikolaidis P. Older HIV-infected patients--an underes-timated population in northern Greece: epidemiology, risk of disease progression and death.Int J Infect Dis. 2013 Oct; 17(10): e883-91. Facteur dimpact 2012: 2.357

    Alexandropoulos T, Haidich AB, Pilalas D, Dardavessis T, Daniilidis M, Arvanitidou M. Characteristics of patients with allergic rhinitis in an outpatient clinic: a retrospective study. Allergol Immunopathol (Madr). 2013 May-Jun; 41(3): 194-200. Facteur dimpact 2012: 1.229

    Haidich AB, Pilalas D, Contopoulos-Ioannidis DG, Ioannidis JP. Most meta-analyses of drug interven-tions have narrow scopes and many focus on specific agents.J Clin Epidemiol. 2013 Apr; 66(4): 371-8. Facteur dimpact 2012: 5.332

    Skoura L, Metallidis S, Pilalas D, Kourelis A, Margariti A, Papadimitriou E, Antoniadou ZA, Chrysanthi-dis T, Tsachouridou O, Kollaras P, Nikolaidis P, Malisiovas N. High rates of transmitted drug resistance among newly-diagnosed antiretroviral nave HIV patients in Northern Greece, data from 2009-2011.Clin Microbiol Infect. 2013 Mar;19(3):E169-72. Facteur dimpact 2012: 4.578

    De Chillou C, Groben L, Magnin-Poull I, Andronache M, Magdi Abbas M, Zhang N, Abdelaal A, Ammar S, Sellal JM, Schwartz J, Brembilla-Perrot B, Aliot E, Marchlinski FE. Localizing the Critical Isthmus of Post-Infarct Ventricular Tachycardia: The Value of Pace Mapping during Sinus Rhythm. Heart Rhythm. 2013 Oct 24. pii: S1547-5271(13)01217-4.

  • A

    ctiv

    its

    scie

    ntifi

    ques

    et a

    cad

    miq

    ues

    au C

    HL

    par

    serv

    ices

    31

    CARDIOLOGIE I MALADIES VASCULAIRES 2012-2013 / 6

    Tchicaya A, Braun M, Lorentz N, Delagardelle C, Beissel J, Wagner DR. Social inequality in awareness of cardiovascular risk factors in patients undergoing coronary angiography. Eur J Prev Cardiol. 2013 Oct; 20(5): 872-9.

    Bousquenaud M, Wagner DR, Maskali F, Marie PY, Devaux Y. Long-term survival after a massive left ventricular infarction evidenced by FDG-PET and leaving intact only the septal wall. Int J Clin Exp Med. 2013; 6(1): 84-5.

    Etudes en cours

    Etude INR (Suivi de lAnticoagulation par Tlmdecine)Dr D Wagner Partenaire : CRP Henri Tudor

    Registre LUCKY : a national feasibility of the Luxembourg acute myocardial infarction registry. Dr D Wagner

    Etude North Pole (Biosignatures to predict outcome after hypothermia for patients surviving cardiac arrest), tude monocentrique visant rechercher des biomarqueurs de bon pronostic neurologique chez les patients traits par hypothermie thrapeutique aprs arrt cardiaque.Collaboration : CHL, INCCI, CRP-Sant. Investigateurs principaux : Dr P. Stammet (ranimation), Dr D Wagner (cardiologie, INCCI, CRP-S), Dr S. Beyenburg (neurologie)

    PROTECT: Patient related outcomes with Endeavor vs Cypher-stenting trials.Dpartement de Cardiologie/Maladies Vasculaires. Dr D Wagner

    SOLSTICE : Studie der Klinischen Wirksamkeit und Sicherheit des Sularflex stent.Dpartement de Cardiologie/Maladies Vasculaires. Dr D Wagner

  • A

    ctiv

    its

    scie

    ntifi

    ques

    et a

    cad

    miq

    ues

    au C

    HL

    par

    serv

    ices

    32

    PNEUMOLOGIE I MALADIES INFECTIEUSESI IMMUNO-ALLERGOLOGIE 2012-2013 / 1

    PNEUMOLOGIE

    Appartenance une Socit Scientifique

    K Abou Hamdan :European Respiratory SocietySocit Luxembourgeoise de PneumologieSocit de Pneumologie de Langue FranaiseBelgian Association for Sleep research and Sleep medicineBritish Sleep SocietyAssociation Franco-Mditerranenne de PneumologieCollge Lorrain de Pathologie Thoracique

    C Charpentier :Socit Luxembourgeoise de PneumologieSocit de Pneumologie de Langue FranaiseEuropean Respiratory SocietySocit Luxembourgeoise dAllergologieSocit Franaise de TabacologieConseil Scientifique de la Franaise de Tabacologie

    R Nati :European Respiratory SocietyDeutsche Gesellschaft fr PneumologieSocit Luxembourgeoise de PneumologieDeutsche Gesellschaft fr Innere MedizinGesellschaft fr Hygiene, Umweltmedizin und PrventivmedizinBelgian Association for Sleep research and Sleep medicine

    M Schlesser :Socit Luxembourgeoise de Pneumologie - PrsidentSocit de Pneumologie de Langue FranaiseEuropean Respiratory SocietyEuropean Cystic Fibrosis SocietySocit Belge de Pneumologie

    G Wirtz :European Respiratory SocietySocit Luxembourgeoise de Pneumologie

  • A

    ctiv

    its

    scie

    ntifi

    ques

    et a

    cad

    miq

    ues

    au C

    HL

    par

    serv

    ices

    33

    PNEUMOLOGIE I MALADIES INFECTIEUSESI IMMUNO-ALLERGOLOGIE 2012-2013 / 2

    Communication un Congrs / Runion Scientifique

    J.L Corhay, W . Vincken, M Schlesser, et al.: Epidemiology of the chronic bronchitis phenotype of COPD patients in Belgium and Luxembourg..European Respiratry Society Vienne 2012

    H.Zhang, C.Lin, M Schlesser et al .: Prioritization of blood based candidate biomarkers for prediction of outcome in lung cancer.ASMS Vancouver 2012

    K Abou Hamdan : Prsentation au Spring Meeting de la B.A.S.S. : Sleep and Breathing. Lige (B), 02.06.12

    C Charpentier : Tabac et pathologies cardiovasculaires,Journe Thmatique : Les Facteurs de Risques Cardiovasculaires : Amphi CHL, 23.03.12

    C Charpentier : Prsidente de la Session I : De la physiopathologie la politique de la Sant en Taba-cologie1re Journe ScienceTAB : Avances scientifiques en tabacologie. Les Journes Scientifiques de lI.R.A.A.T. Lyon (F). 25.10.12

    C Charpentier : Prsidente de la Session : Tabagisme et populations en situation de prcarit. Socit Franaise de Tabacologie. Paris (F). 08.-09.11.12

    M Schlesser : Modalits de prise en charge des patients apniques et du syndrome dobsit hypoven-tilation au GDL.SLEPP-ONLINE, Charleroi, 21.04.2012

    M Schlesser : Gene expression in benign bronchial mucosa in smokers with and without lung cancer: the genetic field of cancerisation. (How to integrate clinical research into practive to improve health decisions? Examples through local projects.)4me Journe de la Recherche Clinique, CRP-Sant, 24.10.12, Novotel Kirchberg

    Dr H De La Barrire, Dr K Abou Hamdan, Dr G WirtzSevrage tabagique en mdecine gnrale, comment relever le dfi au quotidien? Cas cliniques,Chambre de Commerce, Luxembourg, 19.01.13

    K Abou Hamdan : Dpistage du cancer du poumon chez le fumeur.2me SLO Cancer Update Forum. Cancer du poumon : du dpistage au traitement palliatif.Universit de Luxembourg, Kirchberg, 16.03.2013.

    K Abou Hamdan : Cas cliniques. Sevrage tabagique en mdecine gnrale, comment relever le dfi au quotidien?Chambre de Commerce, Luxembourg, 19.01.13

  • A

    ctiv

    its

    scie

    ntifi

    ques

    et a

    cad

    miq

    ues

    au C

    HL

    par

    serv

    ices

    34

    PNEUMOLOGIE I MALADIES INFECTIEUSESI IMMUNO-ALLERGOLOGIE 2012-2013 / 3

    C Charpentier : Asthme allergique, bilan, traitement et suiviLes actualits en mdecine et chirurgie, Alformec, Uni-Lu, 12.01.13

    C Charpentier : Lentretien motivationnel. Sevrage tabagique en mdecine gnrale, comment relever le dfi au quotidien?Chambre de Commerce, Luxembourg, 19.01.13

    C Charpentier : Asthme et Tabac : nouveauts.3me rencontre du Groupe de contact F.R.S.-FNRS Tabacologie.Facult de Mdecine, UCL, Bruxelles (B), 21.09.13

    H De La Barrire : Cas cliniques. Sevrage tabagique en mdecine gnrale, comment relever le dfi au quotidien?Chambre de Commerce, Luxembourg, 19.01.13

    Van Dyck, E, Nazarov P, Muller A,, Berchem G, Schlesser M : Profils dexpression gnique de biopsies de muqueuse bronchique saine de fumeurs atteints ou non dun cancer du poumon non petites cellules. SPLF 2013, Lille, 1-03.02.13.

    Renaud L, Dupont L, Liistro G, De Backer W, Schlesser M, Vincken W., Ninane V, Brusselle G: Impor-tance of inhalation device in asthma and COPD : a consensus using Delphy, ERS 2013, Barcelone

    Vincken W, Potvin M, Reche R, Albert A, Schlesser M : Mapping of COPD guidelines adherence in primary care. ERS 2013, Barcelone, 7-11-09.13.

    Van Dyck E, Nazarov P, Muller A,, Berchem G, Schlesser M : Molecular signatures of non-small cell lung cancer (NSCLC) obtained from gene expression profiling of the benign mucosa of smokers with and without NSLLC or head and neck cancer. ERS 2013, Barcelone, 7-11-09.13.

    G Wirtz : Sevrage tabagique en mdecine gnrale, comment relever le dfi au quotidien? Cas cliniques.Chambre de Commerce, Luxembourg, 19.01.13

    Publications

    Participation ltude Illuminate:C.F Vogelmeier, E.D Bateman, J. Pallante, VKT Alagappan, P. DAndrea, H. Chen, D. Banerji et.al.: Effica-cy and safety of once-daily QVA149 compared with twice salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (Illuminate) : a randomised, double blinded parallel group study. LANCET 2012: S 2213-2600 (12) (Facteur dimpact 2012: 39.060)

    Hilger C, Kler S, Arumugam K, Revets D, Muller CP, Charpentier C, Lehners C, Morisset M, Hentges F. Identification and isolation of a Fel d 1-like molecule as a major rabbit allergen.J Allergy Clin Immunol. 2013 Jun 10. Facteur dimpact 2012: 12.047

  • A

    ctiv

    its

    scie

    ntifi

    ques

    et a

    cad

    miq

    ues

    au C

    HL

    par

    serv

    ices

    35

    PNEUMOLOGIE I MALADIES INFECTIEUSESI IMMUNO-ALLERGOLOGIE 2012-2013 / 4

    Ninane V, Brusselle GG, Louis R, Dupont L, Liistro G, De Backer W, Schlesser M, Vincken W. Usage of inhalation devices in asthma and chronic obstructive pulmonary disease: a Delphi consensus statement. Expert Opin Drug Deliv. 2013 Dec. Facteur dimpact 2012: 4.869

    Corhay JL, Vincken W, Schlesser M, Bossuyt P, Imschoot J. Chronic bronchitis in COPD patients is asso-ciated with increased risk of exacerbations: a cross-sectional multicentre study.Int J Clin Pract. 2013 Dec;67(12):1294-301. . Facteur dimpact 2012: 2.427

    Etudes en cours

    EuLuCA-European Lung Cancer Audit. An observational, non-interventional, study for the feasibility of prospectively collecting demographic and clinical data on lung cancer patients in a Pan-European setting.Etude multicentrique : investigateur principal au Luxembourg : M Schlesser.

    ICEBERG : The management of COPD in primary care : an observational study in Belgium and Luxem-bourg. Etude pluricentrique : W. Vincken, M Schlesser, et al.

    Glow 6 : A 12 weeks multi-center, randomized, double blind, parallel-groupstudy to assess the efficacy, safety and tolerability of the co-administrtaion of NVA237 + indacaterol once daily v.s indacaterol once daily in patients with moderate to severe COPD. Etude multicentrique.Investigateur principal au Luxembourg : M Schlesser.Sponsor : Novartis.

    Biomarker Discovery and Validation in Lung CancerDpartement dHmatologie-Cancrologie. Dr G. Berchem, Dr M SchlesserIntegrated Biobank of Luxembourg (IBBL)

    PROOF-Registry : A prospective observational registry to describe the disease course and outcomes of idiopathic pulmonary fibrosis patients in a real-world clinical setting. Dr M SchlesserSponsor: InterMune International AG

    FLAME : A 52-week treatment, multi-center, randomized, double-blind, double-dummy, parallel-group, active controlled study to compare the effect of QVA149 (indacaterol maleate/ glycopyrronium bromide) with salmeterol/fluticasone on the rate of exacerbations in subjects with moderate to very severe COPDDr M SchlesserSponsor : Novartis.

  • A

    ctiv

    its

    scie

    ntifi

    ques

    et a

    cad

    miq

    ues

    au C

    HL

    par

    serv

    ices

    36

    PNEUMOLOGIE I MALADIES INFECTIEUSESI IMMUNO-ALLERGOLOGIE 2012-2013 / 5

    MALADIES INFECTIEUSES

    Appartenance une Socit Scientifique

    Service National des Maladies infectieuses : Improving Patient Safety in Europe (IPSE) - coordinateur national EUROSURVEILLANCEEuropean Network of Infectious Diseases physicians (EUNID)

    R Hemmer :American Society for Microbiology New York Academy of Sciences International Society of Travel Medicine Society for Healthcare Epidemiology of AmericaInternational AIDS Society Swiss Society of Infectious Diseases Belgian Society of Infectious Diseases and Clinical Microbiology - Founding MemberInfectious Diseases Society of America European Society of Clinical Microbiology and Infectious Diseases

    JC Schmit : Socit Belge de Mdecine Interne European Hematology Society New-York Academy of Sciences American Society for the Advancement of Science Socit Belge dInfectiologie et de Microbiologie Clinique International AIDS Society Alliance for the Prudent Use of Antibiotics European AIDS Clinical Society

    T Staub :Socit de Pathologie infectieuse de langue franaise (SPILF)Socit nationale franaise de mdecine interne (SNFMI)Society for Healthcare Epidemiology of America (SHEA)Conseil Suprieur des Maladies Infectieuses du Luxembourg - PrsidenteGroupe de Travail Antibiothrapie de lUCM - Prsidente

  • A

    ctiv

    its

    scie

    ntifi

    ques

    et a

    cad

    miq

    ues

    au C

    HL

    par

    serv

    ices

    37

    PNEUMOLOGIE I MALADIES INFECTIEUSESI IMMUNO-ALLERGOLOGIE 2012-2013 / 6

    Communication un Congrs / Runion Scientifique

    V Arendt : Prsentation la Confrence Francophone VIH (AFRAVIH). Genve (CH), 24.-28.03.12

    Ho CT, Wang N, Gras A, Schneider S, Schmit JC, Steinmetz A, Devaux C. Anti HIV-1 properties of Aposticho-pus japonicus Selenka (Haishen). Annuel meeting of the European Antiviral Society, Germany, March 2012

    Devaux C, Masquelier C, Lemaire M, Iserentant G, Perez Bercoff D, Ndaysaba G, Karita E, Allen S, Schmit JC, Arendt V. The predominance of the Heterozygous hCCR524 Deletion in Rwandese Indivi-duals Resistant to HIV infection may be Related to a Defect in CCR5 Addressing at the Surface of PBMCs. Mekong Sant, May 2012 , Hanoi Vietnam

    Gras A, Radloff R, Masquelier C, Arumugam K, Karasi JC, Schmit JC, Klein K, Zanger U, Devaux C. : Identification of New CYP2B6 Non-Synonymous SNPs Affecting CYP2B6 Activity in HIV-Infected Patients from Rwanda. 19th Conference on Retroviruses and Opportunistic Infections, March 2012, Seattle USA

    Chevign A, Counson M, Plessria JM, Beaupain N, Devaux C, Schmit JC, Deroo S : Identification of new CCR5 entry inhibitors from human non immunized heavy chain CDR3 repertoires. 19th Conference on Retroviruses and Opportunistic Infections, March 2012, Seattle USA

    Courteille O, Mukabatsinda C, Musafiri S, Reichert P, Gahimbare L, Karasi-Omes C, Arendt V : Etiolo-gie des pneumonies au CHU de Kigali :diagnostic sur lavages bronchoalvolaires. Confrence AFRAVIH 26/03/2012 Genve

    Mukeba Tshialal D, Chioti A., Nachega JB., Arendt V, Gilson G., Moutschen M.: Prvalence de lhyperten-sion artrielle chez les personnes adultes vivant avec le VIH (PVV) dans la ville de Mbuji-Mayi : compa-raison avec des patients adultes non infects par le VIH.AFRAVIH, 2012, Poster N518 , 25-28 mars 2012, Genve (CH)

    D. Struck, S. Ortiou, M. Lemaire, J.Y. Servais, T Staub, V Arendt, D. Perez-Bercoff, C. Devaux, JC Schmit.: COMET applied to HCV subtyping. 10th European Meeting on HIV & Hepatitis: Treatment Strategies and Antiviral Resistance, 28-30 March, 2012, Barcelona, Spain.

    M. Mulinge, M. Lemaire, J.Y. Servais, A. Rybicki, C. Verhofstede, C. Devaux, JC Schmit and D. Perez-Ber-coff. : Comparison of phenotypic and genotypic HIV tropism assay and determination of its accuracy on different subtypes and main CRFs. 10th European Meeting on HIV & Hepatitis: Treatment Strategies and Antiviral Resistance, 28-30 March, 2012, Barcelona, Spain

    J.C. Karasi, F. Musonera, K. Iranyunviye, J.Y. Servais, C. Devaux, A. Binagwaho, V. Arendt, R. Shafer, A. Zolo-pa and JC Schmit : The efficacy of tenofovir and efavirenz in combination with lamivudine or emtricitabine in clinical practice in Europe. J.E. Swartz on behalve of the European Society for Antiviral Resistance. 11th International Congress on Drug Therapy in HIV Infection, 11-15 November, 2012, Glasgow, UK

  • A

    ctiv

    its

    scie

    ntifi

    ques

    et a

    cad

    miq

    ues

    au C

    HL

    par

    serv

    ices

    38

    PNEUMOLOGIE I MALADIES INFECTIEUSESI IMMUNO-ALLERGOLOGIE 2012-2013 / 7

    Assessing the WHO-recommended first-line ART regimens for resource-limited settings: comparison of the relative virologic efficacy and resistance patterns of TDF/3TC/NVP to AZT/*TC/NVP in a Rwandan cohort. XIX International AIDS Conference, July 22-27, 2012, Washington DC, USA

    D Struck, D Perez Bercoff, Staub T, Arendt V, Devaux C, Schmit JC : Large Scale Ancestral Route Re-construction of the Luxembourg HIV Cohort. 11th European Workshop on HIV and hepatitis, Treatment Strategies and Antiviral Drug Resistance, March 2013, Roma.

    L.M. Hofstra, N. Sauvageot, J.Albert, I. Alexiev, F.Garcia, D. Struck, J. Vercauteren, D. Van de Vijver, B. sj, C. Balotta, D. Beshkov, R.J. Camacho, S. Coughlan, A. Griskevicius, O. Hamouda, A. Horban, T. Kolupajeva, L.G. Kostrikis, C. Kcherer, K. Liitsola, M. Linka, O. Mor, C. Nielsen, D. Otelea, D. Paraske-vis, R. Paredes, M. Poljak, E. Puchhammer-Stckl, A. Snnerborg, D. Stanekov, M. Stanojevic, A-M. Vandamme, S. Zidovec Lepej, C.A.B. Boucher, Schmit JC and A.M.J. : Stable proportion but increasing number of HIV-1 diagnoses with transmitted drug resistance across Europe Wensing on behalf of the SPREAD program. 14th European AIDS Conference ,October 2013, Brussels..

    L.M. Hofstra, Pilalas D, I. Alexiev, F. Garcia, O. Hamouda, D. Stanekov, D. Struck, J.Albert, B. sj, C. Balotta, D. Beshkov, R.J. Camacho, S. Coughlan, A. Griskevicius, Z. Grossman, A. Horban, L.G. Kostri-kis, C. Kcherer, K. Liitsola, M. Linka, C. Nielsen, D. Otelea, D. Paraskevis, R. Paredes, M. Poljak, E. Puchhammer-Stckl, M. Stanojevic, E. Van Wijngaerden, S. Zidovec Lepej, C.A.B. Boucher, A.M.J. Wen-sing and Schmit J-C on behalf of the SPREAD program : Europe-wide increase of early detection of HIV-1 infection in MSM, but additional strategies are needed for other risk groups. 14th European AIDS Conference ,October 2013, Brussels..

    K Arumugam, C Devaux and Schmit J-C : Multiple homology model of the human CCR5 chemokine receptor and validation through agonist and antagonist docking. 57th National Meeting of the Biophysical society, February 2013, Philadelphia, Congrs 2013 LRTV

    Ortiou S, Servais JY, Perez-Bercoff D, Fritz J, Vaira D, Delwaide J, Arendt V, Staub T, Schmit JC and Devaux C. : Replication Capacity and Susceptibility to Telaprevir of the T54S Resistant Variant is Modula-ted by Others Hepatitis C Virus NS3 Mutations. 20th Conference on Retroviruses and Opportunistic Infections, March 2013, Atlanta, Congrs 2013 LRTV

    J Vercaueteren, G. Beheydt, M. Properi, P. Libin, S. Imbrechts, R. Camacho, B. Clotet, A. De Luca, Z. Grossman, R. Kaiser, A. Snnerborg, C. Torti, E. Van Wijngaerden, Schmit J-C , M. Zazzi, A-M Geretti, A-M Vandamme, K. Van Laethem : Clinical evaluation of Rega 8. An updated genotypic interpretation system that significantly predicts HIV-Therapy response. 11th European Workshop on HIV and hepatitis, Treatment Strategies and Antiviral Drug Resistance, March 2013, Roma.

  • A

    ctiv

    its

    scie

    ntifi

    ques

    et a

    cad

    miq

    ues

    au C

    HL

    par

    serv

    ices

    39

    PNEUMOLOGIE I MALADIES INFECTIEUSESI IMMUNO-ALLERGOLOGIE 2012-2013 / 8

    Publications

    Zarb P, Coignard B, Griskeviciene J, Muller A, Vankerckhoven V, Weist K, Goossens M, Vaerenberg S, Hopkins S, Catry B, Monnet D, Goossens H, Suetens C; R Hemmer.National Contact Points for the ECDC pilot point prevalence survey; Hospital Contact Points for the ECDC pilot point prevalence survey. The European Centre for Disease Prevention and Control (ECDC) pilot point prevalence survey of health-care-associated infections and antimicrobial use.Euro Surveill. 2012 Nov 15; 17(46). (Facteur dimpact 2012: 5.490)

    Thiberville SD, Schilling S, De Iaco G, Fusco FM, Thomson G, Maltezou HC, Gottschalk R, Brodt RH, Ban-nister B, Puro V, Ippolito G, Brouqui P; .Hemmer R,. EuroNHID Working Group. Diagnostic issues and capabilities in 48 isolation facilities in 16 European countries: data from EuroNHID surveys. BMC Res Notes. 2012 Sep 25; 5:527. (Facteur dimpact 2012: 1.390)

    Maltezou HC, Fusco FM, Schilling S, De Iaco G, Gottschalk R, Brodt HR, Bannister B, Brouqui P, Thomson G, Puro V, Ippolito G; .Hemmer R,.. EuroNHID Working Group. Infection control practices in facilities for highly infectious diseases across Europe.J Hosp Infect. 2012 Jul; 81(3): 184-91. (Facteur dimpact 2012: 2.855)

    Fusco FM, Schilling S, De Iaco G, Brodt HR, Brouqui P, Maltezou HC, Bannister B, Gottschalk R, Thom-son G, Puro V, Ippolito G; .Hemmer R,.. EuroNHID Working Group. Infection control management of patients with suspected highly infectious diseases in emergency departments: data from a survey in 41 facilities in 14 European countries.BMC Infect Dis. 2012 Jan 28; 12:27. (Facteur dimpact 2012: 3.025)

    Reekie J, Kowalska JD, Karpov I, Rockstroh J, Karlsson A, Rakhmanova A, Horban A, Kirk O, Lundgren JD, Mocroft A; .Hemmer R, Staub T,.. EuroSIDA in EuroCoord. Regional differences in AIDS and non-AIDS related mortality in HIV-positive individuals across Europe and Argentina: the EuroSIDA study.PLoS One. 2012; 7(7): e41673. (Facteur dimpact 2012: 3.730)

    Peters L, Grint D, Lundgren JD, Rockstroh JK, Soriano V, Reiss P, Grzeszczuk A, Sambatakou H, Mocroft A, Kirk O; .Hemmer R, Staub T,.. EuroSIDA in EuroCoord. Hepatitis C virus viremia increases the incidence of chronic kidney disease in HIV-infected patients. AIDS. 2012 Sep 24; 26(15): 1917-26. (Facteur dimpact 2012: 6.407)

    Kowalska JD, Reekie J, Mocroft A, Reiss P, Ledergerber B, Gatell J, dArminio Monforte A, Phillips A, Lundgren JD, Kirk O; .Hemmer R, Staub T. EuroSIDA study group. Long-term exposure to com-bination antiretroviral therapy and risk of death from specific causes: no evidence for any previously unidentified increased risk due to antiretroviral therapy.AIDS. 2012 Jan 28; 26(3): 315-23. (Facteur dimpact 2012: 6.407)

  • A

    ctiv

    its

    scie

    ntifi

    ques

    et a

    cad

    miq

    ues

    au C

    HL

    par

    serv

    ices

    40

    PNEUMOLOGIE I MALADIES INFECTIEUSESI IMMUNO-ALLERGOLOGIE 2012-2013 / 9

    May MT, Hogg RS, Justice AC, Shepherd BE, Costagliola D, Ledergerber B, Thibaut R, Gill MJ, Kirk O, van Sighem A, Saag MS, Navarro G, Sobrino-Vegas P, Lampe F, Ingle S, Guest JL, Crane HM, DArminio Monforte A, Vehreschild JJ, Sterne JA; Hemmer R, Staub T, ..Antiretroviral Therapy Cohort Col-laboration (ART-CC). Heterogeneity in outcomes of treated HIV-positive patients in Europe and North America: relation with patient and cohort characteristics.Int J Epidemiol. 2012 Dec; 41(6): 1807-20. (Facteur dimpact 2012: 6.982)

    Petoumenos K, Worm SW, Fontas E, Weber R, De Wit S, Bruyand M, Reiss P, El-Sadr W, Monforte AD, Friis-Mller N, Lundgren JD, Law MG; .Hemmer R, Staub T,.. D:A:D Study Group. Predicting the short-term risk of diabetes in HIV-positive patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study.J Int AIDS Soc. 2012 Oct 10; 15(2): 17426. (Facteur dimpact 2012: 3.936)

    Mocroft A, Bannister WP, Kirk O, Kowalska JD, Reiss P, DArminio-Monforte A, Gatell J, Fisher M, Trocha H, Rakhmanova A, Lundgren JD; .Hemmer R, Staub T,.. EuroSIDA Study in EuroCOORD. The clinical benefits of antiretroviral therapy in severely immunocompromised HIV-1-infected patients with and wit-hout complete viral suppression.Antivir Ther. 2012; 17(7): 1291-300. (Facteur dimpact 2012: 3.073)

    Theys K, Deforche K, Vercauteren J, Libin P, van de Vijver DA, Albert J, Asj B, Balotta C, Bruckova M, Ca-macho RJ, Clotet B, Coughlan S, Grossman Z, Hamouda O, Horban A, Korn K, Kostrikis LG, Kcherer C, Nielsen C, Paraskevis D, Poljak M, Puchhammer-Stockl E, Riva C, Ruiz L, Liitsola K, Schmit JC, Schuur-man R, Snnerborg A, Stanekova D, Stanojevic M, Struck D, Van Laethem K, Wensing AM, Boucher CA, Vandamme AM; .Hemmer R, Staub T,.. SPREAD-programme. Treatment-associated polymorphisms in protease are significantly associated with higher viral load and lower CD4 count in newly diagnosed drug-naive HIV-1 infected patients.Retrovirology. 2012 Oct 3; 9:81. (Facteur dimpact 2012: 5.657)

    Szpakowska M, Fievez V, Arumugan K, van Nuland N, Schmit JC, Chevign A. Function, diversity and therapeutic potential of the N-terminal domain of humanchemokine receptors.Biochem Pharmacol. 2012 Nov 15; 84(10): 1366-80. (Facteur dimpact 2012: 4.576)

    Delhalle S, Schmit JC, Chevign A. Phages and HIV-1: From Display to Interplay.Int J Mol Sci. 2012; 13(4): 4727-94. (Facteur dimpact 2012: 2.464)

    Struck D, Wallis CL, Denisov G, Lambert C, Servais JY, Viana RV, Letsoalo E, Bronze M, Aitken SC, Schuurman R, Stevens W, Schmit JC, Rinke de Wit T, Perez Bercoff D. Automated sequence analysis and editing software for HIV drug resistance testing.J Clin Virol. 2012 May; 54(1): 30-5. (Facteur dimpact 2012: 3.287)

    Origer A, Schmit JC. Prevalence of hepatitis B and C and HIV infections among problem drug users in Luxembourg: self-report versus serological evidence.J Epidemiol Community Health. 2012 Jan; 66(1): 64-8. (Facteur dimpact 2012: 3.392)

  • A

    ctiv

    its

    scie

    ntifi

    ques

    et a

    cad

    miq

    ues

    au C

    HL

    par

    serv

    ices

    41

    PNEUMOLOGIE I MALADIES INFECTIEUSESI IMMUNO-ALLERGOLOGIE 2012-2013 / 10

    Puro V, Fusco FM, Schilling S, Thomson G, De Iaco G, Brouqui P, Maltezou HC, Bannister B, Gottschalk R, Brodt HR, Ippolito G; .Hemmer R,.. European Network For Highly Infectious Diseases. Biosecurity measures in 48 isolation facilities managing highly infectious diseases.Biosecur Bioterror. 2012 Jun; 10(2): 208-14

    Frentz D, Wensing AM, Albert J, Paraskevis D, Abecasis AB, Hamouda O, Jrgensen LB, Kcherer C, Struck D, Schmit JC, sj B, Balotta C, Beshkov D, Camacho RJ, Clotet B, Coughlan S, De Wit S, Griske-vicius A, Grossman Z, Horban A, Kolupajeva T, Korn K, Kostrikis LG, Liitsola K, Linka M, Nielsen C, Otelea D, Paredes R, Poljak M, Puchhammer-Stckl E, Snnerborg A, Stanekova D, Stanojevic M, Vandamme AM, Boucher CA, Van de Vijver DA; SPREAD Programme..Arendt V, Hemmer R, Staub T.. Limited cross-border infections in patients newly diagnosed with HIV in Europe.Retrovirology. 2013 Apr 3; 10:36. Facteur dimpact 2012: 5.657.

    Radloff R, Gras A, Zanger UM, Masquelier C, Arumugam K, Karasi JC, Arendt V, Seguin-Devaux C, Klein K. Novel CYP2B6 enzyme variants in a Rwandese population: functional characterization and assess-ment of in silico prediction tools.Hum Mutat. 2013 May; 34(5): 725-34. Facteur dimpact 2012: 5.213

    Worm SW, Bower M, Reiss P, Bonnet F, Law M, Ftkenheuer G, dArminio Monforte A, Abrams DI, Gru-lich A, Fontas E, Kirk O, Furrer H, De Wit S, Phillips A, Lundgren JD, Sabin CA; D:A:D Study Group.Hemmer R, Staub T. Non-AIDS defining cancers in the D:A:D Study--time trends and predictors of survival: a cohort study. BMC Infect Dis. 2013 Oct 9; 13: 471. Facteur dimpact: 3.025

    Grint D, Peters L, Schwarze-Zander C, Beniowski M, Pradier C, Battegay M, Jevtovic D, Soriano V, Lund-gren JD, Rockstroh JK, Kirk O, Mocroft A; EuroSIDA in EuroCoord. Temporal changes and regional diffe-rences in treatment uptake of hepatitis C therapy in EuroSIDA. Hemmer R, Staub . T HIV Med. 2013 Nov; 14(10): 614-23. Facteur dimpact 2012: Facteur dImpact 2012: 3.155

    Sabin CA, Ryom L, De Wit S, Mocroft A, Phillips AN, Worm SW, Weber R, DArminio Monforte A, Reis